Alzheimer Disease

Neurodegenerative Disorder MONDO:0004975 Pathograph 13 Dementia Neurodegenerative Disease

Alzheimer disease is a progressive neurodegenerative disorder characterized by cognitive decline, memory loss, and behavioral changes. It is the most common cause of dementia, involving the accumulation of amyloid-beta plaques and neurofibrillary tangles in the brain, leading to neuronal death and brain atrophy.

Ask OpenScientist

Ask a research question about Alzheimer Disease. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

8
Pathophys.
6
Phenotypes
7
Hypotheses
1
Gaps
13
Pathograph
8
Genes
5
Treatments
2
Subtypes
6
References
1
Deep Research
7
Hyp. Reports
◆

Subtypes

2
Early-Onset Alzheimer's Disease
Type of Alzheimer's that occurs in individuals younger than 65 and is often associated with genetic factors.
Show evidence (2 references)
PMID:30707186 SUPPORT
"Early-onset Alzheimer disease (AD) is defined as having an age of onset younger than 65 years. ... Early-onset AD comprises about 5% to 6% of cases of AD and includes a substantial percentage of phenotypic variants that differ from the usual amnestic presentation of typical AD. Characteristics..."
This reference clearly supports the definition of Early-Onset Alzheimer's Disease as occurring in individuals younger than 65 and being often associated with genetic factors.
PMID:25998117 SUPPORT
"Young-onset dementia is hereditary, multifactorial, or sporadic. The most common hereditary dementias include Alzheimer disease."
This reference supports the idea that early-onset Alzheimer's disease can be hereditary, aligning with the statement's mention of genetic factors.
Late-Onset Alzheimer's Disease
The most common form of Alzheimer's, occurring in those aged 65 and older.
Show evidence (3 references)
PMID:24429902 SUPPORT
"In both cases, the disease results in severe cognitive dysfunction, among other problems, and the late-onset form of the disease is now considered to be the most common cause of dementia among the elderly."
The literature confirms that late-onset Alzheimer's Disease is the most common form of Alzheimer's and primarily affects those aged 65 and older.
PMID:34120901 SUPPORT
"BACKGROUND: Young onset dementia is associated with a longer time to diagnosis compared to late onset dementia."
The study differentiates between young onset and late onset Alzheimer's Disease, with late onset typically affecting older adults.
PMID:18667359 SUPPORT
"Alzheimer's disease accounts for 60% whereas vascular dementia accounts for approximately 30% of the prevalence. Early-onset familial forms of dementia with single-gene defects occur in Latin America, Asia, and Africa."
The literature indicates that late-onset Alzheimer's Disease is more prevalent compared to early-onset forms.
◈

Mechanistic Hypotheses

7
Amyloid Cascade Model
amyloid_cascade_model CANONICAL Early-Onset Alzheimer's Disease Late-Onset Alzheimer's Disease
Amyloid-beta production, oligomerization, and plaque deposition are modeled as upstream drivers of tau pathology, synaptic toxicity, glial activation, and progressive cognitive decline, especially in APP/PSEN-associated familial Alzheimer disease.
Retained as CANONICAL, but not sufficient as a complete disease explanation: tau burden, vascular injury, immune state, lysosomal clearance, aging, and genetic background modulate how amyloid pathology maps to symptoms.
Pathograph links
Amyloid Plaque Formation -> Neurofibrillary Tangle Formation INDIRECT KNOWN INTERMEDIATES Amyloid-beta accumulation is modeled as an upstream trigger of tau hyperphosphorylation and neurofibrillary tangle formation. Intermediates: Amyloid-beta oligomer and fibril toxicity inducing tau hyperphosphorylation.
Amyloid Plaque Formation -> Synaptic Dysfunction DIRECT Soluble amyloid-beta assemblies are modeled as direct toxic contributors to synaptic dysfunction and cognitive impairment.
Amyloid Plaque Formation -> Neuroinflammation INDIRECT KNOWN INTERMEDIATES Amyloid-beta accumulation and activated microglia can form a reinforcing inflammatory cycle. Intermediates: Microglial activation and inflammatory mediator release.
Vascular Dysfunction -> Amyloid Plaque Formation INDIRECT KNOWN INTERMEDIATES Blood-brain barrier dysfunction and neurovascular-unit impairment are modeled as contributors to brain amyloid-beta accumulation and impaired clearance. Intermediates: Impaired amyloid-beta efflux and neurovascular clearance.
Autophagy-Lysosomal Dysfunction -> Amyloid Plaque Formation INDIRECT KNOWN INTERMEDIATES Impaired autophagy and lysosomal degradation are modeled as contributors to amyloid-beta accumulation through reduced aggregate clearance. Intermediates: Reduced amyloid-beta clearance through defective autophagic flux and lysosomal degradation.
Deep research
OpenScientist citations 28 citations 2026-05-18T21:27:36.693751
Show evidence (2 references)
PMID:25941885 SUPPORT
"The 'amyloid cascade hypothesis' posits that an extracellular build-up of amyloid-beta oligomers (Abeta-os) and polymers (fibrils) subsequently inducing toxic hyperphosphorylated (p)-Tau oligomers (p-Tau-os) and neurofibrillary tangles starts the sporadic late-onset Alzheimer's disease (LOAD)..."
Supports amyloid-beta accumulation as an upstream causal model that induces downstream tau pathology.
PMID:22351073 SUPPORT
"Generation of amyloid peptide (Abeta) is at the beginning of a cascade that leads to Alzheimer's disease (AD)... soluble assembly states of Abeta peptides can cause cognitive problems by disrupting synaptic function..."
Supports amyloid-beta generation as an initiating cascade event with synaptic consequences.
Tau Neurodegeneration Model
tau_neurodegeneration_model CANONICAL Early-Onset Alzheimer's Disease Late-Onset Alzheimer's Disease
Tau hyperphosphorylation and aggregation into neurofibrillary tangles are modeled as proximate drivers of neuronal dysfunction, microtubule disruption, neurodegeneration, and clinical progression.
Pathograph links
Amyloid Plaque Formation -> Neurofibrillary Tangle Formation INDIRECT KNOWN INTERMEDIATES Amyloid-beta accumulation is modeled as an upstream trigger of tau hyperphosphorylation and neurofibrillary tangle formation. Intermediates: Amyloid-beta oligomer and fibril toxicity inducing tau hyperphosphorylation.
Neurofibrillary Tangle Formation -> Synaptic Dysfunction INDIRECT KNOWN INTERMEDIATES Hyperphosphorylated tau and tau aggregates are modeled as toxic contributors to impaired synaptic plasticity and neurotransmitter release. Intermediates: Tau-mediated microtubule disruption and synaptic toxicity.
Autophagy-Lysosomal Dysfunction -> Neurofibrillary Tangle Formation INDIRECT KNOWN INTERMEDIATES Impaired autophagy and lysosomal degradation are modeled as contributors to tau aggregate accumulation through reduced proteostatic clearance. Intermediates: Reduced tau aggregate clearance through defective autophagic flux and lysosomal degradation.
Deep research
OpenScientist citations 38 citations 2026-05-18T21:45:56.028675
Show evidence (2 references)
PMID:21509508 SUPPORT
"Extracellular accumulations of Abeta, hyperphosphorylation of tau and intracellular neurofibrillary tangle formation have been the hallmarks of Alzheimer's Disease (AD)."
Supports tau hyperphosphorylation and tangle formation as central Alzheimer disease pathology.
PMID:19542604 SUPPORT
"Tau protein is the principal component of the neurofibrillary tangles found in Alzheimer's disease (AD), where it is hyperphosphorylated on serine and threonine residues."
Identifies hyperphosphorylated tau as the principal neurofibrillary tangle component in Alzheimer disease.
Synaptic Failure Convergence Model
synaptic_failure_convergence_model CANONICAL Early-Onset Alzheimer's Disease Late-Onset Alzheimer's Disease
Amyloid-beta, tau, inflammatory, vascular, oxidative, and infectious stressors converge on synaptic plasticity, neurotransmitter release, and network function, producing cognitive decline.
Pathograph links
Amyloid Plaque Formation -> Synaptic Dysfunction DIRECT Soluble amyloid-beta assemblies are modeled as direct toxic contributors to synaptic dysfunction and cognitive impairment.
Neurofibrillary Tangle Formation -> Synaptic Dysfunction INDIRECT KNOWN INTERMEDIATES Hyperphosphorylated tau and tau aggregates are modeled as toxic contributors to impaired synaptic plasticity and neurotransmitter release. Intermediates: Tau-mediated microtubule disruption and synaptic toxicity.
Synaptic Dysfunction -> Memory Loss INDIRECT KNOWN INTERMEDIATES Synaptic plasticity failure and aberrant neurotransmitter release are modeled as proximate drivers of cognitive decline, including memory impairment. Intermediates: Hippocampal and cortical network dysfunction.
Oxidative Stress -> Synaptic Dysfunction INDIRECT UNKNOWN INTERMEDIATES Oxidative neuronal injury is modeled as one convergent stressor that worsens synaptic and network function.
Vascular Dysfunction -> Synaptic Dysfunction INDIRECT KNOWN INTERMEDIATES Reduced perfusion and neurovascular-unit injury are modeled as contributors to neuronal and synaptic dysfunction. Intermediates: Inadequate microcirculation in active brain regions.
HSV-1 Reactivation in RORB+ Glutamatergic Neurons -> Synaptic Dysfunction INDIRECT UNKNOWN INTERMEDIATES HSV-1 reactivation in selectively vulnerable cortical neurons is modeled as a possible upstream contributor to loss of synaptic integrity and cognitive-network failure.
Deep research
OpenScientist citations 37 citations 2026-05-18T22:06:17.357864
Show evidence (2 references)
PMID:27662312 SUPPORT
"Compelling evidence suggests that soluble amyloid-beta (Abeta) and hyperphosphorylated tau serve as toxins in the dysfunction of synaptic plasticity and aberrant neurotransmitter (NT) release at synapses consequently causing a cognitive decline in Alzheimer's disease (AD)."
Directly supports synaptic dysfunction as a convergence point downstream of amyloid-beta and tau toxicity.
PMID:12973746 SUPPORT
"Histological studies indicate loss of pyramidal neurones and their synapses in Alzheimer's disease (AD), this together with biochemical evidence suggests presynaptic (and postsynaptic) glutamatergic hypoactivity."
Supports loss of synapses and altered neurotransmission in Alzheimer disease.
Neuroimmune-Glial Amplification Model
neuroimmune_glial_amplification_model ALTERNATIVE Early-Onset Alzheimer's Disease Late-Onset Alzheimer's Disease
Microglia, astrocytes, complement, and inflammasome pathways are modeled as disease-amplifying mechanisms that can both respond to and reinforce amyloid-beta and tau pathology.
Retained as ALTERNATIVE despite strong GWAS support because microglial and astrocyte programs appear context-dependent: the same innate immune pathways can mediate protective amyloid/tau clearance or pathogenic complement, inflammasome, and synapse-loss amplification depending on disease stage, cell state, and genetic background.
Pathograph links
Amyloid Plaque Formation -> Neuroinflammation INDIRECT KNOWN INTERMEDIATES Amyloid-beta accumulation and activated microglia can form a reinforcing inflammatory cycle. Intermediates: Microglial activation and inflammatory mediator release.
Neuroinflammation -> Oxidative Stress DIRECT Activated glial cells are modeled as sources of inflammatory mediators and oxygen radicals that amplify oxidative neuronal injury.
Neuroinflammation -> Vascular Dysfunction INDIRECT KNOWN INTERMEDIATES Neuroinflammation is modeled as a contributor to blood-brain barrier breakdown and neurovascular-unit dysfunction. Intermediates: Inflammatory remodeling of cerebral microvessels and blood-brain barrier injury.
Deep research
OpenScientist citations 38 citations 2026-05-18T22:25:37.317379
Show evidence (2 references)
PMID:28019679 SUPPORT
"NOD-like receptor (NLR) family, pyrin domain containing 3 and 1 inflammasomes, present in myeloid cells and neurons, respectively, represent key components of the innate immune reaction observed in Alzheimer patient brains."
Supports inflammasome-mediated innate immune activation in Alzheimer disease brains.
PMID:23930978 SUPPORT
"A vicious cycle of inflammation has been formed between Abeta accumulation, activated microglia, and microglial inflammatory mediators, which enhance Abeta deposition and neuroinflammation."
Supports a self-reinforcing loop between amyloid-beta deposition and microglial inflammation.
Vascular and Blood-Brain Barrier Clearance Model
vascular_bbb_clearance_model ALTERNATIVE Late-Onset Alzheimer's Disease
Cerebral blood flow changes, neurovascular-unit injury, blood-brain barrier dysfunction, and impaired amyloid-beta clearance are modeled as causal or reinforcing contributors to Alzheimer disease progression.
Pathograph links
Neuroinflammation -> Vascular Dysfunction INDIRECT KNOWN INTERMEDIATES Neuroinflammation is modeled as a contributor to blood-brain barrier breakdown and neurovascular-unit dysfunction. Intermediates: Inflammatory remodeling of cerebral microvessels and blood-brain barrier injury.
Vascular Dysfunction -> Amyloid Plaque Formation INDIRECT KNOWN INTERMEDIATES Blood-brain barrier dysfunction and neurovascular-unit impairment are modeled as contributors to brain amyloid-beta accumulation and impaired clearance. Intermediates: Impaired amyloid-beta efflux and neurovascular clearance.
Vascular Dysfunction -> Synaptic Dysfunction INDIRECT KNOWN INTERMEDIATES Reduced perfusion and neurovascular-unit injury are modeled as contributors to neuronal and synaptic dysfunction. Intermediates: Inadequate microcirculation in active brain regions.
Deep research
OpenScientist citations 35 citations 2026-05-18T22:42:25.259499
Show evidence (2 references)
PMID:28902142 SUPPORT
"Thus, current evidence suggests that BBB dysfunction may causatively and consequently contribute to AD pathogenesis, forming a vicious cycle between brain Abeta accumulation and neurovascular unit impairments during disease progression."
Supports a bidirectional causal cycle between blood-brain barrier dysfunction, amyloid-beta accumulation, and neurovascular injury.
PMID:26898552 SUPPORT
"There is accumulating evidence suggesting that changes in brain perfusion are present long before the clinical symptoms of Alzheimer's disease (AD), perhaps even before amyloid-beta accumulation or brain atrophy."
Supports early cerebral perfusion changes as part of the vascular model.
Autophagy-Lysosomal Clearance Model
autophagy_lysosomal_clearance_model EMERGING Early-Onset Alzheimer's Disease Late-Onset Alzheimer's Disease
Defective autophagic flux, lysosomal transport, and aggregate clearance are modeled as mechanisms that promote amyloid-beta and tau accumulation.
Retained as EMERGING because PSEN1-linked lysosomal acidification evidence provides a strong mechanistic anchor, but the broader contribution of autophagy-lysosomal clearance defects to late-onset Alzheimer disease, amyloid-beta accumulation, and tau accumulation remains incompletely resolved in human longitudinal data.
Pathograph links
Autophagy-Lysosomal Dysfunction -> Amyloid Plaque Formation INDIRECT KNOWN INTERMEDIATES Impaired autophagy and lysosomal degradation are modeled as contributors to amyloid-beta accumulation through reduced aggregate clearance. Intermediates: Reduced amyloid-beta clearance through defective autophagic flux and lysosomal degradation.
Autophagy-Lysosomal Dysfunction -> Neurofibrillary Tangle Formation INDIRECT KNOWN INTERMEDIATES Impaired autophagy and lysosomal degradation are modeled as contributors to tau aggregate accumulation through reduced proteostatic clearance. Intermediates: Reduced tau aggregate clearance through defective autophagic flux and lysosomal degradation.
Deep research
OpenScientist citations 25 citations 2026-05-18T23:00:45.134591
Show evidence (1 reference)
PMID:20541250 SUPPORT Model Organism
"In PS1 null blastocysts, neurons from mice hypomorphic for PS1 or conditionally depleted of PS1, substrate proteolysis and autophagosome clearance during macroautophagy are prevented as a result of a selective impairment of autolysosome acidification and cathepsin activation. These deficits are..."
Demonstrates that PS1 is required for v-ATPase V0a1 targeting to lysosomes; PSEN1 dysfunction therefore directly impairs lysosomal acidification and autophagosome clearance, anchoring the early-onset Alzheimer disease mechanism for this hypothesis group.
HSV-1 Reactivation Model
hsv1_reactivation_model EMERGING Late-Onset Alzheimer's Disease
Latent HSV-1 reactivation in selectively vulnerable RORB+ glutamatergic neurons is modeled as a possible upstream contributor to neuronal vulnerability and later synaptic-network failure.
Retained as EMERGING. The evidence is human, cell-type-resolved, and hypothesis-generating, but causality between HSV-1 expression and Alzheimer disease progression remains unresolved.
Pathograph links
HSV-1 Reactivation in RORB+ Glutamatergic Neurons -> Synaptic Dysfunction INDIRECT UNKNOWN INTERMEDIATES HSV-1 reactivation in selectively vulnerable cortical neurons is modeled as a possible upstream contributor to loss of synaptic integrity and cognitive-network failure.
Deep research
OpenScientist citations 33 citations 2026-05-19T02:39:53.213307Z
Show evidence (2 references)
PMID:42094473 SUPPORT Human Clinical
"Integrative single-nucleus analyses resolve direct evidence of HSV-1 expression in RORB+ glutamatergic neurons, implicating viral reactivation in a neuronal population progressively lost during dementia."
Supports HSV-1 reactivation in a selectively vulnerable Alzheimer-relevant neuronal population.
PMID:42094473 SUPPORT Human Clinical
"identifying recurrent herpes simplex virus 1 (HSV-1) reactivation in healthy but not pathological post-mortem human brain tissue"
Supports the temporal interpretation that HSV-1 reactivation may precede loss of vulnerable neurons rather than simply appear in end-stage pathological tissue.
?

Discussions and Knowledge Gaps

1
Is HSV-1 reactivation in RORB+ glutamatergic neurons CAUSAL for their selective loss in Alzheimer's disease, or a marker of cells already destined to die?
KNOWLEDGE GAP OPEN disc_hsv1_causality
Attached to
pathophysiology#HSV-1 Reactivation in RORB+ Glutamatergic Neurons
Cross-sectional post-mortem evidence establishes the association but cannot resolve causal direction. The answer determines whether antivirals (or pre-emptive HSV-1 suppression) are candidate disease-modifying therapies, or merely a downstream readout of cells already committed to neurodegeneration.
Proposed experiments
HSV-1 reactivation perturbation in human cortical neuron-glia organoids
controlled perturbation experiment
exp_hsv1_organoid_reactivation_causality
Introduce controlled HSV-1 latency/reactivation into human cortical neuron-glia organoids enriched for glutamatergic neurons, then compare RORB+ neuron survival and neuroinflammatory state against matched mock and antiviral-rescue controls.
Model systems
Human cortical neuron-glia organoid
Human pluripotent-stem-cell-derived cortical organoid with glutamatergic neurons and glial support cells, used to test whether viral reactivation precedes neuronal vulnerability in a disease-relevant human cellular context.
ORGANOID namo:Organoid link
human link
RORB+ glutamatergic neuron link microglial cell link
Perturbations
Induced HSV-1 reactivation
pathophysiology#HSV-1 Reactivation in RORB+ Glutamatergic Neurons
Establish latent HSV-1 infection and trigger controlled reactivation to test whether reactivation is sufficient to drive selective RORB+ glutamatergic-neuron loss.
viral process link
Readouts
RORB+ glutamatergic neuron survival
pathophysiology#HSV-1 Reactivation in RORB+ Glutamatergic Neurons
Single-cell and imaging readout of whether RORB+ glutamatergic neurons are selectively depleted after reactivation.
single-cell transcriptomic profiling high-content imaging
Direction: NEGATIVE
Interpretation: Selective loss after reactivation, reduced by antiviral rescue, would support HSV-1 reactivation as a causal injury mechanism.
Neuroinflammatory activation
pathophysiology#Neuroinflammation
Cytokine, glial activation, and stress-response measurements to test whether viral reactivation creates an inflammatory state upstream of neuron loss.
inflammatory response link
multiplex cytokine profiling single-cell transcriptomic profiling
Direction: POSITIVE
Controls
Mock-reactivated isogenic organoids
Matched organoids handled identically without HSV-1 reactivation.
Antiviral rescue arm
Reactivated organoids treated with antiviral suppression before readout.
Decision criterion
HSV-1 reactivation should temporally precede selective RORB+ neuron loss, and antiviral rescue should attenuate both viral signal and neuronal loss.
Would support
pathophysiology#HSV-1 Reactivation in RORB+ Glutamatergic Neurons
Would refute
pathophysiology#HSV-1 Reactivation in RORB+ Glutamatergic Neurons
Show evidence (1 reference)
PMID:42094473 PARTIAL Human Clinical
"Integrative single-nucleus analyses resolve direct evidence of HSV-1 expression in RORB+ glutamatergic neurons, implicating viral reactivation in a neuronal population progressively lost during dementia."
Human post-mortem evidence motivates a perturbational organoid test that can distinguish causal reactivation from end-stage association.
Posed 2026-05-16T00:00:00Z
Seeded from PR 2789 alongside the new HSV-1 pathophysiology node. See the broader discussion of how `discussions:` (this layer) relates to a proposed structural `knowledge_gaps:` layer in https://github.com/monarch-initiative/dismech/issues/2617#issuecomment-4467637580
Show evidence (1 reference)
PMID:42094473 PARTIAL Human Clinical
"Integrative single-nucleus analyses resolve direct evidence of HSV-1 expression in RORB+ glutamatergic neurons, implicating viral reactivation in a neuronal population progressively lost during dementia."
Establishes the association in post-mortem human brain but the cross-sectional design cannot distinguish whether HSV-1 reactivation drives the loss of RORB+ neurons or merely marks neurons destined to die.
⚙

Pathophysiology

8
Amyloid Plaque Formation
Accumulation of amyloid-beta proteins in the brain, forming extracellular plaques that disrupt cell function and communication between neurons.
Amyloid Cascade Model Neuroimmune-Glial Amplification Model Synaptic Failure Convergence Model Tau Neurodegeneration Model
Neurons link Microglia link Astrocytes link
APP link PSEN1 link PSEN2 link
Protein misfolding link ⚠ ABNORMAL Aggregation link Neuroinflammation link
Cerebral Cortex Hippocampus Subcortical Regions
Downstream
Neurofibrillary Tangle Formation Amyloid-beta accumulation is modeled as an upstream trigger of tau hyperphosphorylation and neurofibrillary tangle formation. Amyloid Cascade Model Tau Neurodegeneration Model
Synaptic Dysfunction Soluble amyloid-beta assemblies are modeled as direct toxic contributors to synaptic dysfunction and cognitive impairment. Amyloid Cascade Model Synaptic Failure Convergence Model
Neuroinflammation Amyloid-beta accumulation and activated microglia can form a reinforcing inflammatory cycle. Amyloid Cascade Model Neuroimmune-Glial Amplification Model
Show evidence (8 references)
PMID:28320296 SUPPORT
"These intra- or extracellular insoluble aggregates (fibers or plaques) are hallmarks of many neurodegenerative pathologies including Alzheimer's disease (AD)..."
This reference supports the statement by confirming that amyloid plaques are a hallmark of Alzheimer's disease and discusses the formation and role of amyloid aggregates in AD.
PMID:26322584 SUPPORT
"Alzheimer disease (AD) is characterized by the accumulation of amyloid plaques, which are predominantly composed of amyloid-beta peptide."
This reference supports the statement by indicating that the accumulation of amyloid plaques, composed of amyloid-beta peptide, is a characteristic of Alzheimer's disease.
PMID:22351073 SUPPORT
"Generation of amyloid peptide (Abeta) is at the beginning of a cascade that leads to Alzheimer's disease (AD)... soluble assembly states of Abeta peptides can cause cognitive problems by disrupting synaptic function..."
This reference supports the statement by mentioning that amyloid-beta peptides lead to Alzheimer's disease and cause synaptic dysfunction.
+ 5 more references
Neurofibrillary Tangle Formation
Intracellular accumulation of hyperphosphorylated tau protein, forming twisted fibers that disrupt cellular transport and eventually lead to neuronal death.
Synaptic Failure Convergence Model Tau Neurodegeneration Model
Neurons link
MAPT link
Protein hyperphosphorylation link ↑ INCREASED Microtubule destabilization link
Entorhinal Cortex Hippocampus Neocortex
Downstream
Synaptic Dysfunction Hyperphosphorylated tau and tau aggregates are modeled as toxic contributors to impaired synaptic plasticity and neurotransmitter release. Tau Neurodegeneration Model Synaptic Failure Convergence Model
Show evidence (9 references)
PMID:21509508 SUPPORT
"Extracellular accumulations of Abeta, hyperphosphorylation of tau and intracellular neurofibrillary tangle formation have been the hallmarks of Alzheimer's Disease (AD)."
The article discusses the role of tau hyperphosphorylation and neurofibrillary tangle formation in Alzheimer's Disease, supporting the statement about these processes.
PMID:36001963 SUPPORT
"In Alzheimer's disease and other neurodegenerative tauopathies, tau is found hyperphosphorylated and aggregated in neurofibrillary tangles."
This article supports the statement by mentioning the hyperphosphorylation and aggregation of tau in neurofibrillary tangles in Alzheimer's Disease.
PMID:37266762 SUPPORT
"Tau is a microtubule-associated binding protein in the nervous system that is known for its role in stabilizing microtubules throughout the nerve cell. It accumulates as beta-sheet-rich aggregates and neurofibrillary tangles, leading to an array of different pathologies."
The article confirms that hyperphosphorylated tau leads to the formation of neurofibrillary tangles and disrupts microtubule stabilization, supporting the statement.
+ 6 more references
Synaptic Dysfunction
Progressive loss of synapses and impaired neurotransmitter signaling, leading to disrupted neuronal communication and cognitive decline.
Synaptic Failure Convergence Model
Neurons link
Neurotransmitter release link ↓ DECREASED Synaptic plasticity link ↓ DECREASED
Synapses Neuronal dendrites
Downstream
Memory Loss Synaptic plasticity failure and aberrant neurotransmitter release are modeled as proximate drivers of cognitive decline, including memory impairment. Synaptic Failure Convergence Model
Show evidence (5 references)
PMID:27662312 SUPPORT
"Compelling evidence suggests that soluble amyloid-beta (Abeta) and hyperphosphorylated tau serve as toxins in the dysfunction of synaptic plasticity and aberrant neurotransmitter (NT) release at synapses consequently causing a cognitive decline in Alzheimer's disease (AD)."
The statement is supported by the reference which discusses the role of neurotransmitter release and synaptic plasticity in Alzheimer's Disease, leading to cognitive decline.
PMID:27163751 PARTIAL
"The important role of the hippocampus in age-related cognitive decline and in vulnerability to disease processes such as Alzheimer's disease has prompted this review, which will focus on the complexity of changes that characterize aging, and on the molecular connections that exist between normal..."
The reference supports the cognitive decline aspect but does not elaborate on neurotransmitter signaling or synaptic plasticity in detail.
PMID:12973746 SUPPORT
"Histological studies indicate loss of pyramidal neurones and their synapses in Alzheimer's disease (AD), this together with biochemical evidence suggests presynaptic (and postsynaptic) glutamatergic hypoactivity."
The reference supports the statement by discussing the loss of synapses and impaired glutamatergic neurotransmitter signaling in Alzheimer's Disease.
+ 2 more references
Neuroinflammation
Chronic activation of immune responses in the brain, contributing to neuronal damage and disease progression.
Neuroimmune-Glial Amplification Model Vascular and Blood-Brain Barrier Clearance Model
Microglia link Astrocytes link
Immune activation link ↑ INCREASED Cytokine production link ↑ INCREASED Phagocytosis link
Downstream
Oxidative Stress Activated glial cells are modeled as sources of inflammatory mediators and oxygen radicals that amplify oxidative neuronal injury. Neuroimmune-Glial Amplification Model
Vascular Dysfunction Neuroinflammation is modeled as a contributor to blood-brain barrier breakdown and neurovascular-unit dysfunction. Neuroimmune-Glial Amplification Model Vascular and Blood-Brain Barrier Clearance Model
Show evidence (6 references)
PMID:28019679 SUPPORT
"NOD-like receptor (NLR) family, pyrin domain containing 3 and 1 inflammasomes, present in myeloid cells and neurons, respectively, represent key components of the innate immune reaction observed in Alzheimer patient brains."
The reference supports the involvement of NLRP3 inflammasome activation in Alzheimer's disease, which is part of the immune activation process contributing to neuroinflammation.
PMID:32061803 SUPPORT
"The response of astrocytes to the presence of Abeta, as well astrocytic and microglial interaction and inflammatory cytokine release is also discussed, highlighting a cyclical behaviour of these cells in contributing to AD pathogenesis."
This reference supports the role of astrocytes and microglia in cytokine production and their interaction contributing to Alzheimer's disease pathology.
PMID:35406803 SUPPORT
"Once activated, microglial cells, which are brain-resident immune cells, exert several key actions, including phagocytosis, chemotaxis, and the release of pro- or anti-inflammatory mediators."
This reference supports the involvement of microglia in immune activation, cytokine production, and phagocytosis in Alzheimer's disease.
+ 3 more references
Oxidative Stress
Imbalance between the production of reactive oxygen species and the brain's ability to detoxify them, leading to cellular damage.
Synaptic Failure Convergence Model
Free radical production link ↑ INCREASED Antioxidant defense link ↓ DECREASED
Mitochondria link Cell membranes link
Downstream
Synaptic Dysfunction Oxidative neuronal injury is modeled as one convergent stressor that worsens synaptic and network function. Synaptic Failure Convergence Model
Show evidence (5 references)
PMID:34416493 SUPPORT
"Emerging evidence suggests that accumulated oxidative stress may be one of the key mechanisms causing cognitive aging and neurodegenerative diseases such as Alzheimer's disease (AD)."
The literature supports the role of oxidative stress, including the imbalance between ROS production and antioxidant defenses, in the development of Alzheimer's disease.
PMID:27888001 SUPPORT
"Depending on its level, HNE exerts harmful or protective effects associated with the induction of antioxidant defense mechanisms. These effects make HNE a key player in maintaining redox homeostasis, as well as producing imbalances in this system that participate in aging and the development of..."
This reference supports the involvement of oxidative stress and the imbalance in ROS/RNS in the pathology of neurodegenerative diseases.
PMID:9024330 PARTIAL
"Although the specific process that destroys neurons in patients with Alzheimer's disease (AD) remains obscure, biochemical studies of AD neurohistologic lesions and molecular attempts to map and clone genes in familial AD have contributed greatly to our knowledge of AD."
This reference discusses the uncertainty around the specific processes but acknowledges oxidative stress as a contributing factor.
+ 2 more references
Vascular Dysfunction
Alterations in cerebral blood flow and blood-brain barrier integrity, contributing to neuronal dysfunction and amyloid accumulation.
Amyloid Cascade Model Synaptic Failure Convergence Model Vascular and Blood-Brain Barrier Clearance Model
Endothelial cells link Pericytes link
LRP1 link
Blood-brain barrier regulation link ↕ DYSREGULATED Cerebral blood flow link ↓ DECREASED
Cerebral blood vessels Blood-brain barrier
Downstream
Amyloid Plaque Formation Blood-brain barrier dysfunction and neurovascular-unit impairment are modeled as contributors to brain amyloid-beta accumulation and impaired clearance. Vascular and Blood-Brain Barrier Clearance Model Amyloid Cascade Model
Synaptic Dysfunction Reduced perfusion and neurovascular-unit injury are modeled as contributors to neuronal and synaptic dysfunction. Vascular and Blood-Brain Barrier Clearance Model Synaptic Failure Convergence Model
Show evidence (5 references)
PMID:28902142 SUPPORT
"Thus, current evidence suggests that BBB dysfunction may causatively and consequently contribute to AD pathogenesis, forming a vicious cycle between brain Abeta accumulation and neurovascular unit impairments during disease progression."
This reference supports the statement by indicating that blood-brain barrier (BBB) dysfunction contributes to Alzheimer's disease (AD) pathogenesis, including amyloid-beta (Abeta) accumulation and neurovascular impairments.
PMID:16443487 SUPPORT
"Understanding cerebral degeneration and accumulation of beta-amyloid has generated hopes for discovery of disease-modifying treatments. Progress is needed in understanding the mechanisms that link beta-amyloid accumulation and neuronal death."
This reference supports the statement by discussing the accumulation of beta-amyloid and its link to neuronal death in Alzheimer's disease, which is relevant to the described consequences of vascular dysfunction.
PMID:26898552 SUPPORT
"There is accumulating evidence suggesting that changes in brain perfusion are present long before the clinical symptoms of Alzheimer's disease (AD), perhaps even before amyloid-beta accumulation or brain atrophy."
This reference supports the statement by highlighting the role of cerebral blood flow changes in the early stages of Alzheimer's disease, which is consistent with the described vascular dysfunction.
+ 2 more references
Autophagy-Lysosomal Dysfunction
Impaired autophagy and lysosomal degradation pathways leading to accumulation of protein aggregates and cellular dysfunction.
Amyloid Cascade Model Autophagy-Lysosomal Clearance Model Tau Neurodegeneration Model
Neurons link
Autophagy link ↓ DECREASED Lysosomal degradation link ↓ DECREASED Protein catabolic process link ↓ DECREASED
Hippocampus Cerebral Cortex
Downstream
Amyloid Plaque Formation Impaired autophagy and lysosomal degradation are modeled as contributors to amyloid-beta accumulation through reduced aggregate clearance. Autophagy-Lysosomal Clearance Model Amyloid Cascade Model
Neurofibrillary Tangle Formation Impaired autophagy and lysosomal degradation are modeled as contributors to tau aggregate accumulation through reduced proteostatic clearance. Autophagy-Lysosomal Clearance Model Tau Neurodegeneration Model
Show evidence (1 reference)
PMID:20541250 SUPPORT Model Organism
"In PS1 null blastocysts, neurons from mice hypomorphic for PS1 or conditionally depleted of PS1, substrate proteolysis and autophagosome clearance during macroautophagy are prevented as a result of a selective impairment of autolysosome acidification and cathepsin activation. These deficits are..."
Supports this node's core mechanism by showing that PS1 loss prevents autophagosome clearance through impaired autolysosome acidification and cathepsin activation, with failed v-ATPase V0a1 lysosomal targeting as a causal mechanism.
HSV-1 Reactivation in RORB+ Glutamatergic Neurons
Latent herpes simplex virus 1 (HSV-1) reactivates specifically within RORB+ glutamatergic neurons — a cortical neuronal population selectively vulnerable in Alzheimer's disease. Petabase-scale mining of human sequencing data and single-nucleus analyses detect viral transcripts in this population in HEALTHY (but not pathological) post-mortem brain tissue, consistent with a model in which viral reactivation precedes the progressive loss of this neuronal population during dementia and so is no longer detectable in end-stage disease.
HSV-1 Reactivation Model Synaptic Failure Convergence Model
RORB+ glutamatergic neuron link
HSV-1 release from latency link ↑ INCREASED HSV-1 genome replication link ↑ INCREASED
Cerebral Cortex
Downstream
Synaptic Dysfunction HSV-1 reactivation in selectively vulnerable cortical neurons is modeled as a possible upstream contributor to loss of synaptic integrity and cognitive-network failure. HSV-1 Reactivation Model Synaptic Failure Convergence Model
Show evidence (2 references)
PMID:42094473 SUPPORT Human Clinical
"Integrative single-nucleus analyses resolve direct evidence of HSV-1 expression in RORB+ glutamatergic neurons, implicating viral reactivation in a neuronal population progressively lost during dementia."
The preprint mines >10 petabytes of human sequencing data and uses single-nucleus analyses on post-mortem human brain to localize HSV-1 transcripts specifically to RORB+ glutamatergic neurons, the same cortical population progressively lost in dementia — directly supporting this provisional pathophysiology node.
PMID:42094473 SUPPORT Human Clinical
"identifying recurrent herpes simplex virus 1 (HSV-1) reactivation in healthy but not pathological post-mortem human brain tissue"
Key temporal observation: HSV-1 reactivation is detected in healthy post-mortem brain tissue but is absent from pathological tissue, consistent with a model in which reactivation precedes (rather than follows) the loss of vulnerable neurons.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Alzheimer Disease Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

6
Nervous System 5
Memory Loss VERY_FREQUENT Memory impairment (HP:0002354)
The earliest and most prominent symptom.
Show evidence (1 reference)
PMID:31724515 SUPPORT
"Memory impairment has been considered as one of the earliest clinical hallmarks of Alzheimer's disease."
This reference supports the statement that memory loss is a very frequent and early diagnostic symptom of Alzheimer's disease.
Executive Dysfunction VERY_FREQUENT Cognitive impairment (HP:0100543)
Difficulty in planning, decision-making, and judgment.
Show evidence (3 references)
PMID:24011643 SUPPORT
"Impairment of executive functions is common in neurodegenerative disorders such as Alzheimer's disease."
The literature states that executive dysfunction, which includes difficulties in planning, decision-making, and judgment, is common in Alzheimer's disease.
PMID:31930617 SUPPORT
"Alzheimer's disease (AD) is a neurodegenerative disease characterised by neurocognitive impairments, especially memory impairment, as core symptoms linked to reductions in activities of daily life."
The literature mentions neurocognitive impairments in Alzheimer's disease, which includes executive dysfunction.
PMID:36279224 SUPPORT
"The cognitive decline in cerebrovascular disease, including small vessel disease, is also usually gradual and gradual, progresses slowly, and the underlying defect extends to processing speed, complex attention, and fronto-executive functions."
This reference indicates that executive dysfunction is a common feature in cognitive decline related to Alzheimer's disease.
Behavioral Changes FREQUENT Atypical behavior (HP:0000708)
Includes irritability, depression, and apathy.
Show evidence (4 references)
PMID:38157881 SUPPORT
"Neuropsychiatric or behavioral symptoms of dementia encompass a series of disorders, such as anxiety, depression, apathy, psychosis, and agitation, all commonly present in individuals living with dementia."
The abstract confirms that behavioral changes, including irritability, depression, and apathy, are common in Alzheimer's disease.
PMID:28413709 SUPPORT
"Using the median split approach, greater apathy and lower depression were associated with poorer awareness on the Self-Consciousness Scale (respectively: odds ratio ... = 4.8, p = .03; OR = 4.84, p = .04), and the PCRS (only apathy: OR = 9.3, p = .003)."
This study indicates that apathy and depression are significant behavioral symptoms in Alzheimer's disease.
PMID:34580191 SUPPORT
"Alzheimer Disease and Mood."
The title suggests a focus on mood disturbances, which includes behavioral changes such as depression.
+ 1 more reference
Aphasia FREQUENT Aphasia (HP:0002381)
Difficulty with speech and understanding language.
Show evidence (1 reference)
PMID:24035593 SUPPORT
"Language disorders of degenerative origin are frequently tied to Alzheimer disease (AD) the different variants of which can result in primary and secondary aphasia syndromes."
The literature clearly supports that aphasia, which involves difficulty with speech and understanding language, is a frequent neurologic symptom in Alzheimer's Disease.
Apraxia OCCASIONAL Apraxia (HP:0002186)
Difficulty with motor tasks despite intact motor function.
Show evidence (1 reference)
PMID:36375032 SUPPORT
"Limb apraxia is a common early sign of Alzheimer''s disease (AD) and is thought to occur specifically in early-onset (before the age of 65) AD."
The literature indicates that limb apraxia is a common early sign of Alzheimer's disease, supporting the statement that apraxia can occur in Alzheimer's disease.
Other 1
Agnosia OCCASIONAL
Inability to recognize objects or people.
Show evidence (2 references)
PMID:31930617 NO_EVIDENCE
"Alzheimer's disease (AD) is a neurodegenerative disease characterised by neurocognitive impairments, especially memory impairment, as core symptoms linked to reductions in activities of daily life."
The provided literature discusses various neurocognitive impairments in Alzheimer's disease, but does not specifically mention agnosia.
PMID:29672553 NO_EVIDENCE
"Faces are among the most relevant social stimuli revealing an encounter's identity and actual emotional state. Deficits in facial recognition may be an early sign of cognitive decline leading to social deficits."
The literature discusses deficits in facial recognition in patients with amnestic mild cognitive impairment, but does not explicitly mention agnosia in the context of Alzheimer's disease.
🧬

Genetic Associations

8
APP (Genetic Mutation)
Show evidence (6 references)
PMID:1365885 SUPPORT
"Four mutations involving amino acid substitutions in exons 16 and 17 of the amyloid precursor protein (APP) gene, have been identified which co-segregate with the disease in some families multiply affected by early onset Alzheimer's disease."
This reference supports the association of APP genetic mutations with early-onset Alzheimer's disease.
PMID:33789815 SUPPORT
"This is the first case demonstrating that a low-degree APP gene-dose increase suffices to cause EOAD with prominent amyloid-beta/tau pathology."
This reference supports the role of APP gene mutations in causing early-onset Alzheimer's disease.
PMID:36306459 SUPPORT
"Numerous mutations in amyloid precursor protein (APP) and presenilin 1 and 2 (PSEN1 and PSEN2) have been identified for EOAD, but they can only account for a small proportion of EOAD cases."
This reference supports the association of APP genetic mutations with early-onset Alzheimer's disease.
+ 3 more references
PSEN1 (Genetic Mutation)
Show evidence (6 references)
PMID:31296348 SUPPORT
"Presenilin 1 (PSEN1) gene mutations are the major known genetic cause of early-onset Alzheimer's disease."
The study reports a novel PSEN1 mutation associated with early-onset Alzheimer's disease, supporting the genetic association.
PMID:35487021 SUPPORT
"At present, three early-onset AD genes (APP, PSEN1, PSEN2) and one late-onset AD susceptibility gene apolipoprotein E (APOE) have been determined."
The reference confirms that PSEN1 is one of the genes associated with early-onset Alzheimer's disease.
PMID:36951251 SUPPORT
"A genetic association study was conducted to examine ADAD AAO in 340 individuals with the PSEN1 E280A mutation."
The study discusses a large cohort with a specific PSEN1 mutation associated with early-onset Alzheimer's disease, reinforcing the genetic link.
+ 3 more references
PSEN2 (Genetic Mutation)
Show evidence (3 references)
PMID:35491795 SUPPORT
"The established causative mutations in the APP, PSEN1, and PSEN2 can explain less than 1%, Alzheimer''s disease (AD) patients. Of the identified variants, the PSEN2 mutations are even less common."
The reference confirms that PSEN2 mutations are among the causative factors for early-onset Alzheimer's disease.
PMID:36701017 SUPPORT
"Early-onset AD (EOAD) was defined as AD occurring before age 65. Although it has a high genetic risk, EOAD due to PSEN2 variation is very rare."
The reference supports the association of PSEN2 with early-onset Alzheimer's disease, although it notes that such cases are rare.
PMID:32741831 SUPPORT
"Early-onset familial Alzheimer disease (EOFAD) is caused by heterozygous variants in the presenilin 1 (PSEN1), presenilin 2 (PSEN2), and APP genes."
The reference explicitly states that early-onset familial Alzheimer's disease can be caused by PSEN2 mutations.
APOE (Risk Factor)
TREM2 (Risk Factor)
NLRP3 (Genetic Variant)
PYCARD (Genetic Variant)
LRP1 (Genetic Variant)
💊

Treatments

5
Cholinesterase Inhibitors
Action: cholinesterase inhibitor therapy Ontology label: acetylcholinesterase inhibitor therapy MAXO:0000645
Medications that slow the breakdown of acetylcholine to help with memory and cognitive function (e.g., donepezil, rivastigmine).
Show evidence (5 references)
PMID:24807367 SUPPORT
"Donepezil, galantamine and rivastigmine are commonly used AChEIs in pharmacotherapy for AD, slowing the progression and controlling the symptoms of AD."
The literature supports that cholinesterase inhibitors, including donepezil and rivastigmine, are used to help with symptoms of Alzheimer's disease by slowing the progression and controlling cognitive symptoms.
PMID:28671413 SUPPORT
"Cholinesterase inhibitors, memantine, and a combination of a cholinesterase inhibitor and memantine have produced statistically significant but clinically small delays in various domains of cognitive and functional decline in select patients with Alzheimer disease."
The literature supports the use of cholinesterase inhibitors in delaying cognitive decline in Alzheimer's disease.
PMID:35608903 SUPPORT
"Two classes of drug - cholinesterase inhibitors (donepezil, galantamine and rivastigmine) and memantine - are widely licensed for dementia due to Alzheimer''s disease."
The literature confirms that cholinesterase inhibitors are licensed for use in Alzheimer's disease to alleviate symptoms and delay disease progression.
+ 2 more references
NMDA Receptor Antagonist
Action: Pharmacotherapy NCIT:C15986
Medication that regulates glutamate activity to improve symptoms (e.g., memantine).
Show evidence (3 references)
PMID:12768511 SUPPORT
"Memantine, an antagonist of the glutamatergic NMDA receptor, has been recently approved for the treatment of advanced AD. Due to its action mechanism, memantine is considered a neuroprotective drug, whose utility has been demonstrated in preclinical studies, and a useful symptomatic treatment..."
The abstract confirms that memantine, an NMDA receptor antagonist, is used to treat Alzheimer's Disease by regulating glutamate activity.
PMID:27662322 SUPPORT
"Studies indicate that the distinct outcomes of NMDAR-mediated responses are induced by regionalized receptor activities, followed by different downstream signaling pathways. The activation of synaptic NMDARs initiates plasticity and stimulates cell survival. In contrast, the activation of..."
This abstract highlights that memantine, an NMDA receptor antagonist, helps in blocking the negative effects of excessive NMDAR activity in Alzheimer's Disease.
PMID:20943326 SUPPORT
"The hypothesis proposed is restoration of medium spiny neurons in Huntington's disease using neural progenitor cell implantation and attenuation of glutamate mediated excitotoxicity using a partial glutamate antagonist - Memantine. Memantine can block the NMDA receptors and will prevent excess..."
Although primarily discussing Huntington's Disease, this abstract supports the idea that memantine, an NMDA receptor antagonist, regulates glutamate activity, which is relevant to Alzheimer's Disease treatment.
Cognitive Therapy
Action: behavioral counseling MAXO:0000077
Non-pharmacological interventions to maintain cognitive function.
Show evidence (5 references)
PMID:35621327 SUPPORT
"Cognitive stimulation was found to be an effective intervention for people with moderate Alzheimer's disease because it helped to maintain memory function, executive functions, and attention."
This study specifically highlights the effectiveness of cognitive stimulation in maintaining cognitive functions in patients with moderate Alzheimer's disease.
PMID:28671413 SUPPORT
"Cognitive stimulation programs show benefit in maintenance of cognitive function and improved self-reported quality of life in patients with mild to moderate Alzheimer disease."
This reference supports the statement by indicating that cognitive stimulation programs help maintain cognitive function in patients with mild to moderate Alzheimer's disease.
PMID:37428401 PARTIAL
"CS confers temporary, nonspecific benefits and might slightly reduce dementia risk for neurologically healthy individuals."
This reference indicates that cognitive stimulation offers temporary benefits and might reduce dementia risk, but it is less clear about long-term maintenance of cognitive function specifically in Alzheimer's disease.
+ 2 more references
Supportive Care
Action: supportive care MAXO:0000950
Includes occupational therapy, speech therapy, and caregiver support.
Show evidence (4 references)
PMID:28809650 SUPPORT
"Occupational therapy practitioners play a significant role in supporting adults with Alzheimer's disease and related major neurocognitive disorders, as well as their caregivers, through all phases of the disease process."
The reference highlights the role of occupational therapy in supporting individuals with Alzheimer's disease, which aligns with the statement that includes occupational therapy as part of supportive care.
PMID:38883339 SUPPORT
"The telephone hotline is a useful component of dementia care in Germany and an important contribution to the National Dementia Strategy."
The reference discusses the importance of caregiver support through telephone counseling, aligning with the statement that includes caregiver support as part of supportive care.
PMID:29361068 SUPPORT
"This article first describes the educational, information, and support needs of individuals living dementia and their family caregivers across all stages of Alzheimer's."
The reference discusses the support needs of individuals with Alzheimer's disease and their caregivers, which aligns with the statement that includes caregiver support as part of supportive care.
+ 1 more reference
Lifestyle Modifications
Action: dietary intervention MAXO:0000088
Physical exercise, mental stimulation, and healthy diet to potentially slow disease progression.
Show evidence (4 references)
PMID:35503939 SUPPORT
"The aim of this review is to emphasize the importance of mental activity and aerobic physical exercise as one of the most important health-related activities which may delay the onset or slow down the progression of Alzheimer's dementia."
The review highlights the importance of mental and physical exercise in potentially slowing the progression of Alzheimer's disease.
PMID:32579499 SUPPORT
"Combined with the prevention of AD risk factors such as heart disease, diabetes, and with more recent evidence, microbiome dysfunction, there is a substantial foundation for diet as a modifiable risk factor and preventative measure for AD."
The review suggests that a healthy diet can be a preventative measure for Alzheimer's disease, supporting the role of lifestyle modifications.
PMID:37321363 SUPPORT
"Results showed that eating a healthy diet with plenty of fruits and vegetables, and participation in leisure and physical activities may protect against cognitive decline and cognitive impairment among oldest-old regardless of the APOE genotype."
The systematic review indicates that lifestyle factors such as diet and physical activities may protect against cognitive decline, supporting the statement.
+ 1 more reference
🔬

Biochemical Markers

1
Amyloid Beta (Aβ42) (Elevated)
Context: Found in cerebrospinal fluid and brain tissue.
Show evidence (4 references)
PMID:19661632 SUPPORT
"The core candidate CSF biomarkers Abeta42, total tau (T-tau), and phosphorylated tau (P-tau) have been shown to have a high diagnostic performance to identify AD also in the early phase of the disease."
The literature confirms that Abeta42 is a core biomarker found in cerebrospinal fluid (CSF) and is elevated in Alzheimer's disease.
PMID:31958088 SUPPORT
"Genetic predispositions associated with metabolism of the amyloid-beta protein precursor underlie familial Alzheimer's disease; a form of dementia characterized by early disease onset and elevated levels of cortical amyloid-beta."
The literature confirms that elevated levels of amyloid-beta, including Abeta42, are found in the brain tissue of individuals with Alzheimer's disease.
PMID:38987603 SUPPORT
"beta-amyloid plaques contained a mixture of fibrils, some of which were branched, and protofilaments, arranged in parallel arrays and lattice-like structures."
This reference supports the presence of beta-amyloid in brain tissue, which includes Abeta42, in Alzheimer's disease.
+ 1 more reference
{ }

Source YAML

click to show 
name: Alzheimer Disease
creation_date: '2025-12-04T16:57:31Z'
updated_date: '2026-05-21T03:16:32Z'
description: >
  Alzheimer disease is a progressive neurodegenerative disorder characterized by
  cognitive decline, memory loss, and behavioral changes. It is the most common cause
  of dementia, involving the accumulation of amyloid-beta plaques and neurofibrillary
  tangles in the brain, leading to neuronal death and brain atrophy.
disease_term:
  preferred_term: Alzheimer disease
  term:
    id: MONDO:0004975
    label: Alzheimer disease
category: Neurodegenerative Disorder
parents:
- Dementia
- Neurodegenerative Disease
has_subtypes:
- name: Early-Onset Alzheimer's Disease
  display_name: Early-Onset Alzheimer's Disease
  description: Type of Alzheimer's that occurs in individuals younger than 65 and is often associated with genetic factors.
  evidence:
  - reference: PMID:30707186
    reference_title: "Early-onset Alzheimer Disease and Its Variants."
    supports: SUPPORT
    snippet: Early-onset Alzheimer disease (AD) is defined as having an age of onset younger than 65 years. ... Early-onset AD comprises about 5% to 6% of cases of AD and includes a substantial percentage of phenotypic variants that differ from the usual amnestic presentation of typical AD. Characteristics of early-onset AD in comparison to late-onset AD include a larger genetic predisposition (familial mutations and summed polygenic risk)
    explanation: This reference clearly supports the definition of Early-Onset Alzheimer's Disease as occurring in individuals younger than 65 and being often associated with genetic factors.
  - reference: PMID:25998117
    reference_title: "Genetic testing and counseling in the diagnosis and management of young-onset dementias."
    supports: SUPPORT
    snippet: Young-onset dementia is hereditary, multifactorial, or sporadic. The most common hereditary dementias include Alzheimer disease.
    explanation: This reference supports the idea that early-onset Alzheimer's disease can be hereditary, aligning with the statement's mention of genetic factors.
- name: Late-Onset Alzheimer's Disease
  display_name: Late-Onset Alzheimer's Disease
  description: The most common form of Alzheimer's, occurring in those aged 65 and older.
  evidence:
  - reference: PMID:24429902
    reference_title: "Etiology and pathogenesis of late-onset Alzheimer's disease."
    supports: SUPPORT
    snippet: In both cases, the disease results in severe cognitive dysfunction, among other problems, and the late-onset form of the disease is now considered to be the most common cause of dementia among the elderly.
    explanation: The literature confirms that late-onset Alzheimer's Disease is the most common form of Alzheimer's and primarily affects those aged 65 and older.
  - reference: PMID:34120901
    reference_title: "Time to Diagnosis in Young Onset Alzheimer's Disease: A Population-Based Study from Central Norway."
    supports: SUPPORT
    snippet: 'BACKGROUND: Young onset dementia is associated with a longer time to diagnosis compared to late onset dementia.'
    explanation: The study differentiates between young onset and late onset Alzheimer's Disease, with late onset typically affecting older adults.
  - reference: PMID:18667359
    reference_title: "Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors."
    supports: SUPPORT
    snippet: Alzheimer's disease accounts for 60% whereas vascular dementia accounts for approximately 30% of the prevalence. Early-onset familial forms of dementia with single-gene defects occur in Latin America, Asia, and Africa.
    explanation: The literature indicates that late-onset Alzheimer's Disease is more prevalent compared to early-onset forms.
prevalence:
- population: Global
  notes: An estimated 57.4 million people worldwide were living with dementia in 2019, projected to reach 152.8 million by 2050. Alzheimer disease accounts for 60-70% of dementia cases and is the most common cause of dementia among the elderly.
  evidence:
  - reference: PMID:34998485
    reference_title: "Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019."
    supports: SUPPORT
    snippet: We estimated that the number of people with dementia would increase from 57.4 (95% uncertainty interval 50.4-65.1) million cases globally in 2019 to 152.8 (130.8-175.9) million cases in 2050.
    explanation: Global Burden of Disease Study 2019 analysis providing country-level estimates of dementia prevalence and forecasts to 2050.
  - reference: PMID:31072403
    reference_title: "Alzheimer's disease: risk factors and potentially protective measures."
    supports: SUPPORT
    snippet: Alzheimer's disease (AD) is the most common type of dementia and typically manifests through a progressive loss of episodic memory and cognitive function, subsequently causing language and visuospatial skills deficiencies
    explanation: Review confirming that AD is the most common type of dementia, consistent with estimates that 60-70% of dementia cases are attributable to AD.
mechanistic_hypotheses:
- hypothesis_group_id: amyloid_cascade_model
  hypothesis_label: Amyloid Cascade Model
  status: CANONICAL
  description: >-
    Amyloid-beta production, oligomerization, and plaque deposition are modeled
    as upstream drivers of tau pathology, synaptic toxicity, glial activation,
    and progressive cognitive decline, especially in APP/PSEN-associated
    familial Alzheimer disease.
  applies_to_subtypes:
  - Early-Onset Alzheimer's Disease
  - Late-Onset Alzheimer's Disease
  evidence:
  - reference: PMID:25941885
    reference_title: "Preventing the spread of Alzheimer's disease neuropathology: a role for calcilytics?"
    supports: SUPPORT
    snippet: "The 'amyloid cascade hypothesis' posits that an extracellular build-up of amyloid-beta oligomers (Abeta-os) and polymers (fibrils) subsequently inducing toxic hyperphosphorylated (p)-Tau oligomers (p-Tau-os) and neurofibrillary tangles starts the sporadic late-onset Alzheimer's disease (LOAD)..."
    explanation: Supports amyloid-beta accumulation as an upstream causal model that induces downstream tau pathology.
  - reference: PMID:22351073
    reference_title: "Synaptic dysfunction in Alzheimer's disease."
    supports: SUPPORT
    snippet: "Generation of amyloid peptide (Abeta) is at the beginning of a cascade that leads to Alzheimer's disease (AD)... soluble assembly states of Abeta peptides can cause cognitive problems by disrupting synaptic function..."
    explanation: Supports amyloid-beta generation as an initiating cascade event with synaptic consequences.
  notes: >-
    Retained as CANONICAL, but not sufficient as a complete disease explanation:
    tau burden, vascular injury, immune state, lysosomal clearance, aging, and
    genetic background modulate how amyloid pathology maps to symptoms.
- hypothesis_group_id: tau_neurodegeneration_model
  hypothesis_label: Tau Neurodegeneration Model
  status: CANONICAL
  description: >-
    Tau hyperphosphorylation and aggregation into neurofibrillary tangles are
    modeled as proximate drivers of neuronal dysfunction, microtubule disruption,
    neurodegeneration, and clinical progression.
  applies_to_subtypes:
  - Early-Onset Alzheimer's Disease
  - Late-Onset Alzheimer's Disease
  evidence:
  - reference: PMID:21509508
    reference_title: "Tau mediated neurodegeneration: an insight into Alzheimer's disease pathology."
    supports: SUPPORT
    snippet: "Extracellular accumulations of Abeta, hyperphosphorylation of tau and intracellular neurofibrillary tangle formation have been the hallmarks of Alzheimer's Disease (AD)."
    explanation: Supports tau hyperphosphorylation and tangle formation as central Alzheimer disease pathology.
  - reference: PMID:19542604
    reference_title: "The microtubule-associated protein tau is also phosphorylated on tyrosine."
    supports: SUPPORT
    snippet: "Tau protein is the principal component of the neurofibrillary tangles found in Alzheimer's disease (AD), where it is hyperphosphorylated on serine and threonine residues."
    explanation: Identifies hyperphosphorylated tau as the principal neurofibrillary tangle component in Alzheimer disease.
- hypothesis_group_id: synaptic_failure_convergence_model
  hypothesis_label: Synaptic Failure Convergence Model
  status: CANONICAL
  description: >-
    Amyloid-beta, tau, inflammatory, vascular, oxidative, and infectious
    stressors converge on synaptic plasticity, neurotransmitter release, and
    network function, producing cognitive decline.
  applies_to_subtypes:
  - Early-Onset Alzheimer's Disease
  - Late-Onset Alzheimer's Disease
  evidence:
  - reference: PMID:27662312
    reference_title: "Stress-Induced Synaptic Dysfunction and Neurotransmitter Release in Alzheimer's Disease: Can Neurotransmitters and Neuromodulators be Potential Therapeutic Targets?"
    supports: SUPPORT
    snippet: "Compelling evidence suggests that soluble amyloid-beta (Abeta) and hyperphosphorylated tau serve as toxins in the dysfunction of synaptic plasticity and aberrant neurotransmitter (NT) release at synapses consequently causing a cognitive decline in Alzheimer's disease (AD)."
    explanation: Directly supports synaptic dysfunction as a convergence point downstream of amyloid-beta and tau toxicity.
  - reference: PMID:12973746
    reference_title: "Glutamatergic systems in Alzheimer's disease."
    supports: SUPPORT
    snippet: "Histological studies indicate loss of pyramidal neurones and their synapses in Alzheimer's disease (AD), this together with biochemical evidence suggests presynaptic (and postsynaptic) glutamatergic hypoactivity."
    explanation: Supports loss of synapses and altered neurotransmission in Alzheimer disease.
- hypothesis_group_id: neuroimmune_glial_amplification_model
  hypothesis_label: Neuroimmune-Glial Amplification Model
  status: ALTERNATIVE
  description: >-
    Microglia, astrocytes, complement, and inflammasome pathways are modeled as
    disease-amplifying mechanisms that can both respond to and reinforce
    amyloid-beta and tau pathology.
  applies_to_subtypes:
  - Early-Onset Alzheimer's Disease
  - Late-Onset Alzheimer's Disease
  evidence:
  - reference: PMID:28019679
    reference_title: "Inflammasome activation and innate immunity in Alzheimer's disease."
    supports: SUPPORT
    snippet: "NOD-like receptor (NLR) family, pyrin domain containing 3 and 1 inflammasomes, present in myeloid cells and neurons, respectively, represent key components of the innate immune reaction observed in Alzheimer patient brains."
    explanation: Supports inflammasome-mediated innate immune activation in Alzheimer disease brains.
  - reference: PMID:23930978
    reference_title: "Microglia, neuroinflammation, and beta-amyloid protein in Alzheimer's disease."
    supports: SUPPORT
    snippet: "A vicious cycle of inflammation has been formed between Abeta accumulation, activated microglia, and microglial inflammatory mediators, which enhance Abeta deposition and neuroinflammation."
    explanation: Supports a self-reinforcing loop between amyloid-beta deposition and microglial inflammation.
  notes: >-
    Retained as ALTERNATIVE despite strong GWAS support because microglial and
    astrocyte programs appear context-dependent: the same innate immune pathways
    can mediate protective amyloid/tau clearance or pathogenic complement,
    inflammasome, and synapse-loss amplification depending on disease stage,
    cell state, and genetic background.
- hypothesis_group_id: vascular_bbb_clearance_model
  hypothesis_label: Vascular and Blood-Brain Barrier Clearance Model
  status: ALTERNATIVE
  description: >-
    Cerebral blood flow changes, neurovascular-unit injury, blood-brain barrier
    dysfunction, and impaired amyloid-beta clearance are modeled as causal or
    reinforcing contributors to Alzheimer disease progression.
  applies_to_subtypes:
  - Late-Onset Alzheimer's Disease
  evidence:
  - reference: PMID:28902142
    reference_title: "Blood-Brain Barrier Dysfunction and the Pathogenesis of Alzheimer's Disease."
    supports: SUPPORT
    snippet: "Thus, current evidence suggests that BBB dysfunction may causatively and consequently contribute to AD pathogenesis, forming a vicious cycle between brain Abeta accumulation and neurovascular unit impairments during disease progression."
    explanation: Supports a bidirectional causal cycle between blood-brain barrier dysfunction, amyloid-beta accumulation, and neurovascular injury.
  - reference: PMID:26898552
    reference_title: "The Utility of Cerebral Blood Flow as a Biomarker of Preclinical Alzheimer's Disease."
    supports: SUPPORT
    snippet: "There is accumulating evidence suggesting that changes in brain perfusion are present long before the clinical symptoms of Alzheimer's disease (AD), perhaps even before amyloid-beta accumulation or brain atrophy."
    explanation: Supports early cerebral perfusion changes as part of the vascular model.
- hypothesis_group_id: autophagy_lysosomal_clearance_model
  hypothesis_label: Autophagy-Lysosomal Clearance Model
  status: EMERGING
  description: >-
    Defective autophagic flux, lysosomal transport, and aggregate clearance are
    modeled as mechanisms that promote amyloid-beta and tau accumulation.
  applies_to_subtypes:
  - Early-Onset Alzheimer's Disease
  - Late-Onset Alzheimer's Disease
  evidence:
  - reference: PMID:20541250
    reference_title: "Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer-related PS1 mutations."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "In PS1 null blastocysts, neurons from mice hypomorphic for PS1 or conditionally depleted of PS1, substrate proteolysis and autophagosome clearance during macroautophagy are prevented as a result of a selective impairment of autolysosome acidification and cathepsin activation. These deficits are caused by failed PS1-dependent targeting of the v-ATPase V0a1 subunit to lysosomes."
    explanation: >-
      Demonstrates that PS1 is required for v-ATPase V0a1 targeting to
      lysosomes; PSEN1 dysfunction therefore directly impairs lysosomal
      acidification and autophagosome clearance, anchoring the early-onset
      Alzheimer disease mechanism for this hypothesis group.
  notes: >-
    Retained as EMERGING because PSEN1-linked lysosomal acidification evidence
    provides a strong mechanistic anchor, but the broader contribution of
    autophagy-lysosomal clearance defects to late-onset Alzheimer disease,
    amyloid-beta accumulation, and tau accumulation remains incompletely
    resolved in human longitudinal data.
- hypothesis_group_id: hsv1_reactivation_model
  hypothesis_label: HSV-1 Reactivation Model
  status: EMERGING
  description: >-
    Latent HSV-1 reactivation in selectively vulnerable RORB+ glutamatergic
    neurons is modeled as a possible upstream contributor to neuronal
    vulnerability and later synaptic-network failure.
  applies_to_subtypes:
  - Late-Onset Alzheimer's Disease
  evidence:
  - reference: PMID:42094473
    reference_title: "Resolving human neuronal herpesvirus reactivation via petabase-scale association studies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Integrative single-nucleus analyses resolve direct evidence of HSV-1 expression in RORB+ glutamatergic neurons, implicating viral reactivation in a neuronal population progressively lost during dementia."
    explanation: Supports HSV-1 reactivation in a selectively vulnerable Alzheimer-relevant neuronal population.
  - reference: PMID:42094473
    reference_title: "Resolving human neuronal herpesvirus reactivation via petabase-scale association studies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "identifying recurrent herpes simplex virus 1 (HSV-1) reactivation in healthy but not pathological post-mortem human brain tissue"
    explanation: Supports the temporal interpretation that HSV-1 reactivation may precede loss of vulnerable neurons rather than simply appear in end-stage pathological tissue.
  notes: >-
    Retained as EMERGING. The evidence is human, cell-type-resolved, and
    hypothesis-generating, but causality between HSV-1 expression and Alzheimer
    disease progression remains unresolved.
pathophysiology:
- name: Amyloid Plaque Formation
  description: Accumulation of amyloid-beta proteins in the brain, forming extracellular plaques that disrupt cell function and communication between neurons.
  cell_types:
  - preferred_term: Neurons
    term:
      id: CL:0000540
      label: neuron
  - preferred_term: Microglia
    term:
      id: CL:0000129
      label: microglial cell
  - preferred_term: Astrocytes
    term:
      id: CL:0000127
      label: astrocyte
  biological_processes:
  - preferred_term: Protein misfolding
    modifier: ABNORMAL
    term:
      id: GO:0006457
      label: protein folding
  - preferred_term: Aggregation
    term:
      id: GO:0034205
      label: amyloid-beta formation
  - preferred_term: Neuroinflammation
    term:
      id: GO:0150076
      label: neuroinflammatory response
  locations:
  - preferred_term: Cerebral Cortex
  - preferred_term: Hippocampus
  - preferred_term: Subcortical Regions
  chemical_entities:
  - preferred_term: Amyloid-beta peptides (Aβ40, Aβ42)
  genes:
  - preferred_term: APP
    term:
      id: hgnc:620
      label: APP
  - preferred_term: PSEN1
    term:
      id: hgnc:9508
      label: PSEN1
  - preferred_term: PSEN2
    term:
      id: hgnc:9509
      label: PSEN2
  pathways:
  - preferred_term: Amyloid precursor protein processing
    term:
      id: GO:0042982
      label: amyloid precursor protein metabolic process
  mechanisms:
  - Beta-secretase (BACE1) cleavage of APP
  - Gamma-secretase cleavage of APP C-terminal fragment
  consequences:
  - Synaptic Dysfunction
  - Neuroinflammation
  evidence:
  - reference: PMID:28320296
    reference_title: "Biological Basis for Amyloidogenesis in Alzheimer's Disease."
    supports: SUPPORT
    snippet: These intra- or extracellular insoluble aggregates (fibers or plaques) are hallmarks of many neurodegenerative pathologies including Alzheimer's disease (AD)...
    explanation: This reference supports the statement by confirming that amyloid plaques are a hallmark of Alzheimer's disease and discusses the formation and role of amyloid aggregates in AD.
  - reference: PMID:26322584
    reference_title: "η-Secretase processing of APP inhibits neuronal activity in the hippocampus."
    supports: SUPPORT
    snippet: Alzheimer disease (AD) is characterized by the accumulation of amyloid plaques, which are predominantly composed of amyloid-beta peptide.
    explanation: This reference supports the statement by indicating that the accumulation of amyloid plaques, composed of amyloid-beta peptide, is a characteristic of Alzheimer's disease.
  - reference: PMID:22351073
    reference_title: "Synaptic dysfunction in Alzheimer's disease."
    supports: SUPPORT
    snippet: Generation of amyloid peptide (Abeta) is at the beginning of a cascade that leads to Alzheimer's disease (AD)... soluble assembly states of Abeta peptides can cause cognitive problems by disrupting synaptic function...
    explanation: This reference supports the statement by mentioning that amyloid-beta peptides lead to Alzheimer's disease and cause synaptic dysfunction.
  - reference: PMID:10911965
    reference_title: "Transgenic mouse models of Alzheimer's disease."
    supports: SUPPORT
    snippet: Alzheimer's disease (AD) pathology is characterized by A beta peptide-containing plaques, neurofibrillary tangles consisting of hyperphosphorylated tau, extensive neuritic degeneration, and distinct neuron loss.
    explanation: This reference supports the statement by describing Alzheimer's disease pathology, including amyloid-beta peptide-containing plaques.
  - reference: PMID:10702374
    reference_title: "Cellular and molecular basis of beta-amyloid precursor protein metabolism."
    supports: SUPPORT
    snippet: beta-amyloid (Abeta) is the main constituent of the amyloidogenic plaques which are a primary pathological hallmark of Alzheimer's disease...
    explanation: This reference supports the statement by confirming that beta-amyloid is the main constituent of amyloid plaques, a hallmark of Alzheimer's disease.
  - reference: PMID:36555791
    reference_title: "PS1 Affects the Pathology of Alzheimer's Disease by Regulating BACE1 Distribution in the ER and BACE1 Maturation in the Golgi Apparatus."
    supports: SUPPORT
    snippet: Neuritic plaques are one of the major pathological hallmarks of Alzheimer's disease. They are formed by the aggregation of extracellular amyloid-beta protein (Abeta)...
    explanation: This reference supports the statement by indicating that neuritic plaques, formed by the aggregation of amyloid-beta protein, are a hallmark of Alzheimer's disease.
  - reference: PMID:25941885
    reference_title: "Preventing the spread of Alzheimer's disease neuropathology: a role for calcilytics?"
    supports: SUPPORT
    snippet: The 'amyloid cascade hypothesis' posits that an extracellular build-up of amyloid-beta oligomers (Abeta-os) and polymers (fibrils) subsequently inducing toxic hyperphosphorylated (p)-Tau oligomers (p-Tau-os) and neurofibrillary tangles starts the sporadic late-onset Alzheimer's disease (LOAD)...
    explanation: This reference supports the statement by discussing the amyloid cascade hypothesis, which involves the build-up of amyloid-beta leading to Alzheimer's disease.
  - reference: PMID:16611586
    reference_title: "The involvement of lipid rafts in Alzheimer's disease."
    supports: SUPPORT
    snippet: The amyloidogenesis occurring in Alzheimer's disease represents a fundamental membrane-related pathology... the amyloid-beta peptide (Abeta), which accumulates extracellularly as plaques in the brains of Alzheimer's disease patients...
    explanation: This reference supports the statement by describing the accumulation of amyloid-beta peptide as plaques in Alzheimer's disease.
  downstream:
  - target: Neurofibrillary Tangle Formation
    description: Amyloid-beta accumulation is modeled as an upstream trigger of tau hyperphosphorylation and neurofibrillary tangle formation.
    hypothesis_groups:
    - amyloid_cascade_model
    - tau_neurodegeneration_model
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Amyloid-beta oligomer and fibril toxicity inducing tau hyperphosphorylation.
    evidence:
    - reference: PMID:25941885
      reference_title: "Preventing the spread of Alzheimer's disease neuropathology: a role for calcilytics?"
      supports: SUPPORT
      snippet: "The 'amyloid cascade hypothesis' posits that an extracellular build-up of amyloid-beta oligomers (Abeta-os) and polymers (fibrils) subsequently inducing toxic hyperphosphorylated (p)-Tau oligomers (p-Tau-os) and neurofibrillary tangles starts the sporadic late-onset Alzheimer's disease (LOAD)..."
      explanation: Supports the modeled edge from amyloid-beta buildup to downstream tau pathology.
  - target: Synaptic Dysfunction
    description: Soluble amyloid-beta assemblies are modeled as direct toxic contributors to synaptic dysfunction and cognitive impairment.
    hypothesis_groups:
    - amyloid_cascade_model
    - synaptic_failure_convergence_model
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:22351073
      reference_title: "Synaptic dysfunction in Alzheimer's disease."
      supports: SUPPORT
      snippet: "Generation of amyloid peptide (Abeta) is at the beginning of a cascade that leads to Alzheimer's disease (AD)... soluble assembly states of Abeta peptides can cause cognitive problems by disrupting synaptic function..."
      explanation: Directly links soluble amyloid-beta assemblies to synaptic dysfunction and cognitive problems.
  - target: Neuroinflammation
    description: Amyloid-beta accumulation and activated microglia can form a reinforcing inflammatory cycle.
    hypothesis_groups:
    - amyloid_cascade_model
    - neuroimmune_glial_amplification_model
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Microglial activation and inflammatory mediator release.
    evidence:
    - reference: PMID:23930978
      reference_title: "Microglia, neuroinflammation, and beta-amyloid protein in Alzheimer's disease."
      supports: SUPPORT
      snippet: "A vicious cycle of inflammation has been formed between Abeta accumulation, activated microglia, and microglial inflammatory mediators, which enhance Abeta deposition and neuroinflammation."
      explanation: Supports a reinforcing edge between amyloid-beta accumulation and neuroinflammatory activation.
- name: Neurofibrillary Tangle Formation
  description: Intracellular accumulation of hyperphosphorylated tau protein, forming twisted fibers that disrupt cellular transport and eventually lead to neuronal death.
  cell_types:
  - preferred_term: Neurons
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: Protein hyperphosphorylation
    modifier: INCREASED
    term:
      id: GO:0006468
      label: protein phosphorylation
  - preferred_term: Microtubule destabilization
    term:
      id: GO:0007019
      label: microtubule depolymerization
  locations:
  - preferred_term: Entorhinal Cortex
  - preferred_term: Hippocampus
  - preferred_term: Neocortex
  chemical_entities:
  - preferred_term: Tau protein
  genes:
  - preferred_term: MAPT
    term:
      id: hgnc:6893
      label: MAPT
  pathways:
  - preferred_term: Tau phosphorylation cascade
    term:
      id: GO:0006468
      label: protein phosphorylation
  mechanisms:
  - Hyperphosphorylation of tau by various kinases
  - Aggregation of hyperphosphorylated tau
  consequence: Synaptic Dysfunction
  evidence:
  - reference: PMID:21509508
    reference_title: "Tau mediated neurodegeneration: an insight into Alzheimer's disease pathology."
    supports: SUPPORT
    snippet: Extracellular accumulations of Abeta, hyperphosphorylation of tau and intracellular neurofibrillary tangle formation have been the hallmarks of Alzheimer's Disease (AD).
    explanation: The article discusses the role of tau hyperphosphorylation and neurofibrillary tangle formation in Alzheimer's Disease, supporting the statement about these processes.
  - reference: PMID:36001963
    reference_title: "Disruption of nuclear envelope integrity as a possible initiating event in tauopathies."
    supports: SUPPORT
    snippet: In Alzheimer's disease and other neurodegenerative tauopathies, tau is found hyperphosphorylated and aggregated in neurofibrillary tangles.
    explanation: This article supports the statement by mentioning the hyperphosphorylation and aggregation of tau in neurofibrillary tangles in Alzheimer's Disease.
  - reference: PMID:37266762
    reference_title: "The Role of Tau Proteoforms in Health and Disease."
    supports: SUPPORT
    snippet: Tau is a microtubule-associated binding protein in the nervous system that is known for its role in stabilizing microtubules throughout the nerve cell. It accumulates as beta-sheet-rich aggregates and neurofibrillary tangles, leading to an array of different pathologies.
    explanation: The article confirms that hyperphosphorylated tau leads to the formation of neurofibrillary tangles and disrupts microtubule stabilization, supporting the statement.
  - reference: PMID:19542604
    reference_title: "The microtubule-associated protein tau is also phosphorylated on tyrosine."
    supports: SUPPORT
    snippet: Tau protein is the principal component of the neurofibrillary tangles found in Alzheimer's disease (AD), where it is hyperphosphorylated on serine and threonine residues.
    explanation: This article supports the statement by identifying hyperphosphorylated tau as the main component of neurofibrillary tangles in Alzheimer's Disease.
  - reference: PMID:28100644
    reference_title: "Multicellular hypothesis for the pathogenesis of Alzheimer's disease."
    supports: SUPPORT
    snippet: These multicellular interactions are initiated by insoluble tangles of phosphorylated tau protein and plaques of amyloid peptides.
    explanation: This article supports the statement by discussing how phosphorylated tau protein tangles initiate multicellular interactions in Alzheimer's Disease.
  - reference: PMID:2135393
    reference_title: "Tau protein and neurodegeneration."
    supports: SUPPORT
    snippet: The most common of these conditions is Alzheimer's disease, in which microtubules are lost from neurites that fill up with filamentous structures. One component of the filamentous structures is the microtubule-associated protein (MAP), tau.
    explanation: The article supports the statement by explaining how tau protein is involved in the formation of filamentous structures in Alzheimer's Disease, leading to microtubule destabilization.
  - reference: PMID:12859672
    reference_title: "Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms."
    supports: SUPPORT
    snippet: Neurofibrillary tangles are composed of insoluble aggregates of the microtubule-associated protein tau. In Alzheimer's disease the accumulation of neurofibrillary tangles occurs in the absence of tau mutations.
    explanation: This article supports the statement by describing the composition and formation of neurofibrillary tangles from tau protein in Alzheimer's Disease.
  - reference: PMID:31903881
    reference_title: "Targeting Tau Hyperphosphorylation via Kinase Inhibition: Strategy to Address Alzheimer's Disease."
    supports: SUPPORT
    snippet: Hyperphosphorylation of tau protein leads to aggregation of tau into paired helical filaments like structures which are major constituents of neurofibrillary tangles, a hallmark of Alzheimer's disease.
    explanation: The article supports the statement by linking tau hyperphosphorylation and aggregation to the formation of neurofibrillary tangles in Alzheimer's Disease.
  - reference: PMID:23948895
    reference_title: "Tauopathies and tau oligomers."
    supports: SUPPORT
    snippet: Tauopathies are neurodegenerative diseases characterized behaviorally by dementia and neuropathologically by neurofibrillary tangles and neuronal loss.
    explanation: The article supports the statement by describing tauopathies, including Alzheimer's Disease, as being characterized by neurofibrillary tangles and neuronal loss.
  downstream:
  - target: Synaptic Dysfunction
    description: Hyperphosphorylated tau and tau aggregates are modeled as toxic contributors to impaired synaptic plasticity and neurotransmitter release.
    hypothesis_groups:
    - tau_neurodegeneration_model
    - synaptic_failure_convergence_model
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Tau-mediated microtubule disruption and synaptic toxicity.
    evidence:
    - reference: PMID:27662312
      reference_title: "Stress-Induced Synaptic Dysfunction and Neurotransmitter Release in Alzheimer's Disease: Can Neurotransmitters and Neuromodulators be Potential Therapeutic Targets?"
      supports: SUPPORT
      snippet: "Compelling evidence suggests that soluble amyloid-beta (Abeta) and hyperphosphorylated tau serve as toxins in the dysfunction of synaptic plasticity and aberrant neurotransmitter (NT) release at synapses consequently causing a cognitive decline in Alzheimer's disease (AD)."
      explanation: Supports hyperphosphorylated tau as a synaptic toxin in Alzheimer disease.
- name: Synaptic Dysfunction
  description: Progressive loss of synapses and impaired neurotransmitter signaling, leading to disrupted neuronal communication and cognitive decline.
  cell_types:
  - preferred_term: Neurons
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: Neurotransmitter release
    modifier: DECREASED
    term:
      id: GO:0007269
      label: neurotransmitter secretion
  - preferred_term: Synaptic plasticity
    modifier: DECREASED
    term:
      id: GO:0048167
      label: regulation of synaptic plasticity
  locations:
  - preferred_term: Synapses
  - preferred_term: Neuronal dendrites
  chemical_entities:
  - preferred_term: Acetylcholine
    term:
      id: CHEBI:15355
      label: acetylcholine
  - preferred_term: Glutamate
    term:
      id: CHEBI:14321
      label: glutamate(1-)
  - preferred_term: GABA
    term:
      id: CHEBI:16865
      label: gamma-aminobutyric acid
  pathways:
  - preferred_term: Synaptic vesicle recycling
    term:
      id: GO:0099504
      label: synaptic vesicle cycle
  - preferred_term: Neurotransmitter receptor signaling
    term:
      id: GO:0050804
      label: modulation of chemical synaptic transmission
  consequence: Oxidative Stress
  evidence:
  - reference: PMID:27662312
    reference_title: "Stress-Induced Synaptic Dysfunction and Neurotransmitter Release in Alzheimer's Disease: Can Neurotransmitters and Neuromodulators be Potential Therapeutic Targets?"
    supports: SUPPORT
    snippet: Compelling evidence suggests that soluble amyloid-beta (Abeta) and hyperphosphorylated tau serve as toxins in the dysfunction of synaptic plasticity and aberrant neurotransmitter (NT) release at synapses consequently causing a cognitive decline in Alzheimer's disease (AD).
    explanation: The statement is supported by the reference which discusses the role of neurotransmitter release and synaptic plasticity in Alzheimer's Disease, leading to cognitive decline.
  - reference: PMID:27163751
    reference_title: "Molecular and cellular aspects of age-related cognitive decline and Alzheimer's disease."
    supports: PARTIAL
    snippet: The important role of the hippocampus in age-related cognitive decline and in vulnerability to disease processes such as Alzheimer's disease has prompted this review, which will focus on the complexity of changes that characterize aging, and on the molecular connections that exist between normal aging and Alzheimer's disease.
    explanation: The reference supports the cognitive decline aspect but does not elaborate on neurotransmitter signaling or synaptic plasticity in detail.
  - reference: PMID:12973746
    reference_title: "Glutamatergic systems in Alzheimer's disease."
    supports: SUPPORT
    snippet: Histological studies indicate loss of pyramidal neurones and their synapses in Alzheimer's disease (AD), this together with biochemical evidence suggests presynaptic (and postsynaptic) glutamatergic hypoactivity.
    explanation: The reference supports the statement by discussing the loss of synapses and impaired glutamatergic neurotransmitter signaling in Alzheimer's Disease.
  - reference: PMID:33232936
    reference_title: "Alterations of GABA B receptors in the APP/PS1 mouse model of Alzheimer's disease."
    supports: SUPPORT
    snippet: In the present study, we examined alterations in several GABA-specific targets in the APP/PS1 mouse model at different ages... Overall, our study provides evidence of altered GABAergic signaling in an amyloid model of AD at a time point consistent with AD-related deficits.
    explanation: The reference supports the statement by providing evidence of altered GABAergic signaling and its role in Alzheimer's Disease.
  - reference: PMID:9024330
    reference_title: "Neurobiology of Alzheimer's disease."
    supports: SUPPORT
    snippet: The major component of the extraneuronal neuritic plaque is beta-amyloid (A beta), which may be neurotoxic. The major component of the intraneuronal neurofibrillary tangle is hyperphosphorylated tau protein.
    explanation: The reference supports the statement by discussing neurotoxic components that contribute to synaptic dysfunction and cognitive decline in Alzheimer's Disease.
  downstream:
  - target: Memory Loss
    description: Synaptic plasticity failure and aberrant neurotransmitter release are modeled as proximate drivers of cognitive decline, including memory impairment.
    hypothesis_groups:
    - synaptic_failure_convergence_model
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Hippocampal and cortical network dysfunction.
    evidence:
    - reference: PMID:27662312
      reference_title: "Stress-Induced Synaptic Dysfunction and Neurotransmitter Release in Alzheimer's Disease: Can Neurotransmitters and Neuromodulators be Potential Therapeutic Targets?"
      supports: SUPPORT
      snippet: "Compelling evidence suggests that soluble amyloid-beta (Abeta) and hyperphosphorylated tau serve as toxins in the dysfunction of synaptic plasticity and aberrant neurotransmitter (NT) release at synapses consequently causing a cognitive decline in Alzheimer's disease (AD)."
      explanation: Supports synaptic dysfunction as a proximate mechanism for cognitive decline.
- name: Neuroinflammation
  description: Chronic activation of immune responses in the brain, contributing to neuronal damage and disease progression.
  cell_types:
  - preferred_term: Microglia
    term:
      id: CL:0000129
      label: microglial cell
  - preferred_term: Astrocytes
    term:
      id: CL:0000127
      label: astrocyte
  biological_processes:
  - preferred_term: Immune activation
    modifier: INCREASED
    term:
      id: GO:0002253
      label: activation of immune response
  - preferred_term: Cytokine production
    modifier: INCREASED
    term:
      id: GO:0001816
      label: cytokine production
  - preferred_term: Phagocytosis
    term:
      id: GO:0006909
      label: phagocytosis
  chemical_entities:
  - preferred_term: Cytokines
  - preferred_term: Chemokines
  - preferred_term: Complement proteins
  pathways:
  - preferred_term: NF-κB signaling
    term:
      id: GO:0007249
      label: canonical NF-kappaB signal transduction
  - preferred_term: NLRP3 inflammasome activation
    term:
      id: GO:0044546
      label: NLRP3 inflammasome complex assembly
  consequences:
  - Oxidative Stress
  - Vascular Dysfunction
  evidence:
  - reference: PMID:28019679
    reference_title: "Inflammasome activation and innate immunity in Alzheimer's disease."
    supports: SUPPORT
    snippet: NOD-like receptor (NLR) family, pyrin domain containing 3 and 1 inflammasomes, present in myeloid cells and neurons, respectively, represent key components of the innate immune reaction observed in Alzheimer patient brains.
    explanation: The reference supports the involvement of NLRP3 inflammasome activation in Alzheimer's disease, which is part of the immune activation process contributing to neuroinflammation.
  - reference: PMID:32061803
    reference_title: "Cyclical amyloid beta-astrocyte activity induces oxidative stress in Alzheimer's disease."
    supports: SUPPORT
    snippet: The response of astrocytes to the presence of Abeta, as well astrocytic and microglial interaction and inflammatory cytokine release is also discussed, highlighting a cyclical behaviour of these cells in contributing to AD pathogenesis.
    explanation: This reference supports the role of astrocytes and microglia in cytokine production and their interaction contributing to Alzheimer's disease pathology.
  - reference: PMID:35406803
    reference_title: "Microglial Endocannabinoid Signalling in AD."
    supports: SUPPORT
    snippet: Once activated, microglial cells, which are brain-resident immune cells, exert several key actions, including phagocytosis, chemotaxis, and the release of pro- or anti-inflammatory mediators.
    explanation: This reference supports the involvement of microglia in immune activation, cytokine production, and phagocytosis in Alzheimer's disease.
  - reference: PMID:21546088
    reference_title: "Complement in the brain."
    supports: SUPPORT
    snippet: In age related diseases, such as Alzheimer's disease (AD), accumulating amyloid proteins elicit complement activation and a local, chronic inflammatory response that leads to attraction and activation of glial cells that, under such activation conditions, can produce neurotoxic substances, including pro-inflammatory cytokines and oxygen radicals.
    explanation: This reference supports the involvement of complement proteins, cytokines, and oxidative stress in Alzheimer's disease.
  - reference: PMID:23930978
    reference_title: "Microglia, neuroinflammation, and beta-amyloid protein in Alzheimer's disease."
    supports: SUPPORT
    snippet: A vicious cycle of inflammation has been formed between Abeta accumulation, activated microglia, and microglial inflammatory mediators, which enhance Abeta deposition and neuroinflammation.
    explanation: Review of microglia dual roles in AD pathogenesis, describing the vicious cycle between Aβ accumulation, microglial activation, and inflammatory mediator release.
  - reference: PMID:36357946
    reference_title: "Microglia as Central Protagonists in the Chronic Stress Response."
    supports: SUPPORT
    snippet: Furthermore, exposure to chronic stress alters the phenotype of microglia, a population of innate immune cells that reside in the CNS parenchyma.
    explanation: This reference supports the role of microglia as key players in immune activation and neuroinflammation.
  downstream:
  - target: Oxidative Stress
    description: Activated glial cells are modeled as sources of inflammatory mediators and oxygen radicals that amplify oxidative neuronal injury.
    hypothesis_groups:
    - neuroimmune_glial_amplification_model
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:21546088
      reference_title: "Complement in the brain."
      supports: SUPPORT
      snippet: "In age related diseases, such as Alzheimer's disease (AD), accumulating amyloid proteins elicit complement activation and a local, chronic inflammatory response that leads to attraction and activation of glial cells that, under such activation conditions, can produce neurotoxic substances, including pro-inflammatory cytokines and oxygen radicals."
      explanation: Supports activated glia as a source of cytokines and oxygen radicals in Alzheimer disease.
  - target: Vascular Dysfunction
    description: Neuroinflammation is modeled as a contributor to blood-brain barrier breakdown and neurovascular-unit dysfunction.
    hypothesis_groups:
    - neuroimmune_glial_amplification_model
    - vascular_bbb_clearance_model
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Inflammatory remodeling of cerebral microvessels and blood-brain barrier injury.
    evidence:
    - reference: PMID:36293539
      reference_title: "Physiological and Pathological Remodeling of Cerebral Microvessels."
      supports: PARTIAL
      snippet: "Aberrant remodeling of microvesselsis associated with blood-brain barrier breakdown, development of neuroinflammation, inadequate microcirculation in active brain regions, and leads to the dysfunction of the neurovascular unit and progressive neurological deficits."
      explanation: Partially supports coupling among neuroinflammation, blood-brain barrier breakdown, and neurovascular-unit dysfunction.
- name: Oxidative Stress
  description: Imbalance between the production of reactive oxygen species and the brain's ability to detoxify them, leading to cellular damage.
  biological_processes:
  - preferred_term: Free radical production
    modifier: INCREASED
    term:
      id: GO:1903409
      label: reactive oxygen species biosynthetic process
  - preferred_term: Antioxidant defense
    modifier: DECREASED
    term:
      id: GO:0006979
      label: response to oxidative stress
  cellular_components:
  - preferred_term: Mitochondria
    term:
      id: GO:0005739
      label: mitochondrion
  - preferred_term: Cell membranes
    term:
      id: GO:0005886
      label: plasma membrane
  chemical_entities:
  - preferred_term: Reactive oxygen species (ROS)
    term:
      id: CHEBI:26523
      label: reactive oxygen species
  - preferred_term: Reactive nitrogen species (RNS)
    term:
      id: CHEBI:62764
      label: reactive nitrogen species
  pathways:
  - preferred_term: Mitochondrial electron transport chain
    term:
      id: GO:0022904
      label: respiratory electron transport chain
  - preferred_term: NADPH oxidase activation
  consequences:
  - Amyloid Plaque Formation
  - Neurofibrillary Tangle Formation
  evidence:
  - reference: PMID:34416493
    reference_title: "Emerging roles of oxidative stress in brain aging and Alzheimer's disease."
    supports: SUPPORT
    snippet: Emerging evidence suggests that accumulated oxidative stress may be one of the key mechanisms causing cognitive aging and neurodegenerative diseases such as Alzheimer's disease (AD).
    explanation: The literature supports the role of oxidative stress, including the imbalance between ROS production and antioxidant defenses, in the development of Alzheimer's disease.
  - reference: PMID:27888001
    reference_title: "Antioxidants and HNE in redox homeostasis."
    supports: SUPPORT
    snippet: Depending on its level, HNE exerts harmful or protective effects associated with the induction of antioxidant defense mechanisms. These effects make HNE a key player in maintaining redox homeostasis, as well as producing imbalances in this system that participate in aging and the development of pathological conditions.
    explanation: This reference supports the involvement of oxidative stress and the imbalance in ROS/RNS in the pathology of neurodegenerative diseases.
  - reference: PMID:9024330
    reference_title: "Neurobiology of Alzheimer's disease."
    supports: PARTIAL
    snippet: Although the specific process that destroys neurons in patients with Alzheimer's disease (AD) remains obscure, biochemical studies of AD neurohistologic lesions and molecular attempts to map and clone genes in familial AD have contributed greatly to our knowledge of AD.
    explanation: This reference discusses the uncertainty around the specific processes but acknowledges oxidative stress as a contributing factor.
  - reference: PMID:25772897
    reference_title: "Pathological mechanisms in progressive multiple sclerosis."
    supports: PARTIAL
    snippet: Key elements driving neurodegeneration include microglia activation, chronic oxidative injury, accumulation of mitochondrial damage in axons, and age-related iron accumulation in the human brain.
    explanation: This reference supports the involvement of oxidative stress and mitochondrial damage in neurodegeneration but does not specifically focus on Alzheimer's disease.
  - reference: PMID:33164705
    reference_title: "Neuroprotective effects of natural compounds on neurotoxin-induced oxidative stress and cell apoptosis."
    supports: SUPPORT
    snippet: Oxidative stress-induced neuronal apoptosis plays a pivotal role in pathogenesis of neurodegeneration.
    explanation: This reference supports the role of oxidative stress in neurodegeneration, which is relevant to Alzheimer's disease.
  downstream:
  - target: Synaptic Dysfunction
    description: Oxidative neuronal injury is modeled as one convergent stressor that worsens synaptic and network function.
    hypothesis_groups:
    - synaptic_failure_convergence_model
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:34416493
      reference_title: "Emerging roles of oxidative stress in brain aging and Alzheimer's disease."
      supports: PARTIAL
      snippet: "Emerging evidence suggests that accumulated oxidative stress may be one of the key mechanisms causing cognitive aging and neurodegenerative diseases such as Alzheimer's disease (AD)."
      explanation: Supports oxidative stress as a disease-relevant neurodegenerative mechanism, though the specific synaptic edge remains partly inferred.
- name: Vascular Dysfunction
  description: Alterations in cerebral blood flow and blood-brain barrier integrity, contributing to neuronal dysfunction and amyloid accumulation.
  cell_types:
  - preferred_term: Endothelial cells
    term:
      id: CL:0000115
      label: endothelial cell
  - preferred_term: Pericytes
    term:
      id: CL:0000669
      label: pericyte
  biological_processes:
  - preferred_term: Blood-brain barrier regulation
    modifier: DYSREGULATED
    term:
      id: GO:1905603
      label: regulation of blood-brain barrier permeability
  - preferred_term: Cerebral blood flow
    modifier: DECREASED
    term:
      id: GO:0120275
      label: cerebral blood circulation
  locations:
  - preferred_term: Cerebral blood vessels
  - preferred_term: Blood-brain barrier
  pathways:
  - preferred_term: Neurovascular coupling
  - preferred_term: Perivascular drainage
  genes:
  - preferred_term: LRP1
    term:
      id: hgnc:6692
      label: LRP1
  consequences:
  - Amyloid Plaque Formation
  - Oxidative Stress
  evidence:
  - reference: PMID:28902142
    reference_title: "Blood-Brain Barrier Dysfunction and the Pathogenesis of Alzheimer's Disease."
    supports: SUPPORT
    snippet: Thus, current evidence suggests that BBB dysfunction may causatively and consequently contribute to AD pathogenesis, forming a vicious cycle between brain Abeta accumulation and neurovascular unit impairments during disease progression.
    explanation: This reference supports the statement by indicating that blood-brain barrier (BBB) dysfunction contributes to Alzheimer's disease (AD) pathogenesis, including amyloid-beta (Abeta) accumulation and neurovascular impairments.
  - reference: PMID:16443487
    reference_title: "Pathophysiology of Alzheimer's disease."
    supports: SUPPORT
    snippet: Understanding cerebral degeneration and accumulation of beta-amyloid has generated hopes for discovery of disease-modifying treatments. Progress is needed in understanding the mechanisms that link beta-amyloid accumulation and neuronal death.
    explanation: This reference supports the statement by discussing the accumulation of beta-amyloid and its link to neuronal death in Alzheimer's disease, which is relevant to the described consequences of vascular dysfunction.
  - reference: PMID:26898552
    reference_title: "The Utility of Cerebral Blood Flow as a Biomarker of Preclinical Alzheimer's Disease."
    supports: SUPPORT
    snippet: There is accumulating evidence suggesting that changes in brain perfusion are present long before the clinical symptoms of Alzheimer's disease (AD), perhaps even before amyloid-beta accumulation or brain atrophy.
    explanation: This reference supports the statement by highlighting the role of cerebral blood flow changes in the early stages of Alzheimer's disease, which is consistent with the described vascular dysfunction.
  - reference: PMID:36293539
    reference_title: "Physiological and Pathological Remodeling of Cerebral Microvessels."
    supports: SUPPORT
    snippet: Aberrant remodeling of microvesselsis associated with blood-brain barrier breakdown, development of neuroinflammation, inadequate microcirculation in active brain regions, and leads to the dysfunction of the neurovascular unit and progressive neurological deficits.
    explanation: This reference supports the statement by describing how microvascular remodeling and blood-brain barrier breakdown contribute to neurovascular unit dysfunction and neurological deficits, relevant to Alzheimer's disease.
  - reference: PMID:35289012
    reference_title: "Pathological changes within the cerebral vasculature in Alzheimer's disease: New perspectives."
    supports: SUPPORT
    snippet: We consider how abnormalities of the constituent cells of the neurovascular unit - particularly of endothelial cells and pericytes - and impairment of the blood-brain barrier (BBB) impact on the pathogenesis of AD.
    explanation: This reference supports the statement by discussing the role of endothelial cells and pericytes in blood-brain barrier impairment and Alzheimer's disease pathogenesis.
  downstream:
  - target: Amyloid Plaque Formation
    description: Blood-brain barrier dysfunction and neurovascular-unit impairment are modeled as contributors to brain amyloid-beta accumulation and impaired clearance.
    hypothesis_groups:
    - vascular_bbb_clearance_model
    - amyloid_cascade_model
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Impaired amyloid-beta efflux and neurovascular clearance.
    evidence:
    - reference: PMID:28902142
      reference_title: "Blood-Brain Barrier Dysfunction and the Pathogenesis of Alzheimer's Disease."
      supports: SUPPORT
      snippet: "Thus, current evidence suggests that BBB dysfunction may causatively and consequently contribute to AD pathogenesis, forming a vicious cycle between brain Abeta accumulation and neurovascular unit impairments during disease progression."
      explanation: Supports a causal and consequential cycle between BBB dysfunction, amyloid-beta accumulation, and neurovascular-unit impairment.
  - target: Synaptic Dysfunction
    description: Reduced perfusion and neurovascular-unit injury are modeled as contributors to neuronal and synaptic dysfunction.
    hypothesis_groups:
    - vascular_bbb_clearance_model
    - synaptic_failure_convergence_model
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Inadequate microcirculation in active brain regions.
    evidence:
    - reference: PMID:36293539
      reference_title: "Physiological and Pathological Remodeling of Cerebral Microvessels."
      supports: PARTIAL
      snippet: "Aberrant remodeling of microvesselsis associated with blood-brain barrier breakdown, development of neuroinflammation, inadequate microcirculation in active brain regions, and leads to the dysfunction of the neurovascular unit and progressive neurological deficits."
      explanation: Supports neurovascular-unit dysfunction and inadequate microcirculation as contributors to neurological deficits.
- name: Autophagy-Lysosomal Dysfunction
  description: Impaired autophagy and lysosomal degradation pathways leading to accumulation of protein aggregates and cellular dysfunction.
  cell_types:
  - preferred_term: Neurons
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: Autophagy
    modifier: DECREASED
    term:
      id: GO:0006914
      label: autophagy
  - preferred_term: Lysosomal degradation
    modifier: DECREASED
    term:
      id: GO:0007041
      label: lysosomal transport
  - preferred_term: Protein catabolic process
    modifier: DECREASED
    term:
      id: GO:0030163
      label: protein catabolic process
  locations:
  - preferred_term: Hippocampus
  - preferred_term: Cerebral Cortex
  mechanisms:
  - Impaired autophagic flux and autophagosome-lysosome fusion
  - Defective lysosomal acidification
  - Accumulation of autophagic vacuoles containing Aβ
  consequences:
  - Amyloid Plaque Formation
  - Neurofibrillary Tangle Formation
  evidence:
  - reference: PMID:20541250
    reference_title: "Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer-related PS1 mutations."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "In PS1 null blastocysts, neurons from mice hypomorphic for PS1 or conditionally depleted of PS1, substrate proteolysis and autophagosome clearance during macroautophagy are prevented as a result of a selective impairment of autolysosome acidification and cathepsin activation. These deficits are caused by failed PS1-dependent targeting of the v-ATPase V0a1 subunit to lysosomes."
    explanation: >-
      Supports this node's core mechanism by showing that PS1 loss prevents
      autophagosome clearance through impaired autolysosome acidification and
      cathepsin activation, with failed v-ATPase V0a1 lysosomal targeting as a
      causal mechanism.
  notes: Beclin-1/VPS34 complex deficits, p62 accumulation, and faulty autolysosome acidification contribute to impaired clearance of Aβ and tau aggregates.
  downstream:
  - target: Amyloid Plaque Formation
    description: Impaired autophagy and lysosomal degradation are modeled as contributors to amyloid-beta accumulation through reduced aggregate clearance.
    hypothesis_groups:
    - autophagy_lysosomal_clearance_model
    - amyloid_cascade_model
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Reduced amyloid-beta clearance through defective autophagic flux and lysosomal degradation.
  - target: Neurofibrillary Tangle Formation
    description: Impaired autophagy and lysosomal degradation are modeled as contributors to tau aggregate accumulation through reduced proteostatic clearance.
    hypothesis_groups:
    - autophagy_lysosomal_clearance_model
    - tau_neurodegeneration_model
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Reduced tau aggregate clearance through defective autophagic flux and lysosomal degradation.
- name: HSV-1 Reactivation in RORB+ Glutamatergic Neurons
  description: >-
    Latent herpes simplex virus 1 (HSV-1) reactivates specifically within RORB+
    glutamatergic neurons — a cortical neuronal population selectively
    vulnerable in Alzheimer's disease. Petabase-scale mining of human
    sequencing data and single-nucleus analyses detect viral transcripts in
    this population in HEALTHY (but not pathological) post-mortem brain
    tissue, consistent with a model in which viral reactivation precedes the
    progressive loss of this neuronal population during dementia and so is no
    longer detectable in end-stage disease.
  mechanism_confidence: PROVISIONAL
  cell_types:
  - preferred_term: RORB+ glutamatergic neuron
    term:
      id: CL:0000679
      label: glutamatergic neuron
  biological_processes:
  - preferred_term: HSV-1 release from latency
    modifier: INCREASED
    term:
      id: GO:0019046
      label: release from viral latency
  - preferred_term: HSV-1 genome replication
    modifier: INCREASED
    term:
      id: GO:0019079
      label: viral genome replication
  locations:
  - preferred_term: Cerebral Cortex
  mechanisms:
  - Reactivation of latent HSV-1 in long-lived cortical neurons
  - Selective viral expression in RORB+ glutamatergic neuron subpopulations
  consequences:
  - Synaptic Dysfunction
  evidence:
  - reference: PMID:42094473
    reference_title: "Resolving human neuronal herpesvirus reactivation via petabase-scale association studies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Integrative single-nucleus analyses resolve direct evidence of HSV-1 expression in RORB+ glutamatergic neurons, implicating viral reactivation in a neuronal population progressively lost during dementia."
    explanation: >-
      The preprint mines >10 petabytes of human sequencing data and uses
      single-nucleus analyses on post-mortem human brain to localize HSV-1
      transcripts specifically to RORB+ glutamatergic neurons, the same
      cortical population progressively lost in dementia — directly
      supporting this provisional pathophysiology node.
  - reference: PMID:42094473
    reference_title: "Resolving human neuronal herpesvirus reactivation via petabase-scale association studies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "identifying recurrent herpes simplex virus 1 (HSV-1) reactivation in healthy but not pathological post-mortem human brain tissue"
    explanation: >-
      Key temporal observation: HSV-1 reactivation is detected in healthy
      post-mortem brain tissue but is absent from pathological tissue,
      consistent with a model in which reactivation precedes (rather than
      follows) the loss of vulnerable neurons.
  downstream:
  - target: Synaptic Dysfunction
    description: HSV-1 reactivation in selectively vulnerable cortical neurons is modeled as a possible upstream contributor to loss of synaptic integrity and cognitive-network failure.
    hypothesis_groups:
    - hsv1_reactivation_model
    - synaptic_failure_convergence_model
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:42094473
      reference_title: "Resolving human neuronal herpesvirus reactivation via petabase-scale association studies."
      supports: PARTIAL
      evidence_source: HUMAN_CLINICAL
      snippet: "Integrative single-nucleus analyses resolve direct evidence of HSV-1 expression in RORB+ glutamatergic neurons, implicating viral reactivation in a neuronal population progressively lost during dementia."
      explanation: Supports HSV-1 reactivation in a vulnerable neuronal population, while the synaptic dysfunction edge remains an inferred downstream consequence.
  notes: >-
    Provisional / emerging hypothesis. The herpesvirus-reactivation model of
    Alzheimer's pathogenesis is not yet established as canonical, but the
    petabase-scale single-nucleus evidence ties viral reactivation to a
    specific, selectively vulnerable cortical neuronal population (RORB+
    glutamatergic neurons). The signal is present in healthy but not
    pathological brain — interpreted by the authors as reactivation preceding
    the progressive loss of these neurons. Causality between HSV-1
    expression and neuronal loss remains correlative in this work. The
    downstream "Synaptic Dysfunction" consequence is inferred from
    neuronal-population loss rather than directly demonstrated in the cited
    paper. Upstream drivers (e.g., aging-related immune decline, latent HSV-1
    burden) are not yet represented as separate nodes in this entry.
phenotypes:
- category: Cognitive
  name: Memory Loss
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: The earliest and most prominent symptom.
  evidence:
  - reference: PMID:31724515
    reference_title: "Assessment of Memory Impairment in Early Diagnosis of Alzheimer's Disease."
    supports: SUPPORT
    snippet: Memory impairment has been considered as one of the earliest clinical hallmarks of Alzheimer's disease.
    explanation: This reference supports the statement that memory loss is a very frequent and early diagnostic symptom of Alzheimer's disease.
  phenotype_term:
    preferred_term: Memory impairment
    term:
      id: HP:0002354
      label: Memory impairment
- category: Cognitive
  name: Executive Dysfunction
  frequency: VERY_FREQUENT
  notes: Difficulty in planning, decision-making, and judgment.
  evidence:
  - reference: PMID:24011643
    reference_title: "Executive functions in clinical and preclinical Alzheimer's disease."
    supports: SUPPORT
    snippet: Impairment of executive functions is common in neurodegenerative disorders such as Alzheimer's disease.
    explanation: The literature states that executive dysfunction, which includes difficulties in planning, decision-making, and judgment, is common in Alzheimer's disease.
  - reference: PMID:31930617
    reference_title: "Anosognosia in patients with Alzheimer's disease: current perspectives."
    supports: SUPPORT
    snippet: Alzheimer's disease (AD) is a neurodegenerative disease characterised by neurocognitive impairments, especially memory impairment, as core symptoms linked to reductions in activities of daily life.
    explanation: The literature mentions neurocognitive impairments in Alzheimer's disease, which includes executive dysfunction.
  - reference: PMID:36279224
    reference_title: "[Vascular cognitive impairment]."
    supports: SUPPORT
    snippet: The cognitive decline in cerebrovascular disease, including small vessel disease, is also usually gradual and gradual, progresses slowly, and the underlying defect extends to processing speed, complex attention, and fronto-executive functions.
    explanation: This reference indicates that executive dysfunction is a common feature in cognitive decline related to Alzheimer's disease.
  phenotype_term:
    preferred_term: Impaired executive functioning
    term:
      id: HP:0100543
      label: Cognitive impairment
- category: Psychiatric
  name: Behavioral Changes
  frequency: FREQUENT
  notes: Includes irritability, depression, and apathy.
  evidence:
  - reference: PMID:38157881
    reference_title: "Behavioral or neuropsychiatric symptoms of Alzheimer's disease: from psychopathology to pharmacological management."
    supports: SUPPORT
    snippet: Neuropsychiatric or behavioral symptoms of dementia encompass a series of disorders, such as anxiety, depression, apathy, psychosis, and agitation, all commonly present in individuals living with dementia.
    explanation: The abstract confirms that behavioral changes, including irritability, depression, and apathy, are common in Alzheimer's disease.
  - reference: PMID:28413709
    reference_title: "Awareness, apathy, and depression in Alzheimer's disease and mild cognitive impairment."
    supports: SUPPORT
    snippet: 'Using the median split approach, greater apathy and lower depression were associated with poorer awareness on the Self-Consciousness Scale (respectively: odds ratio ... = 4.8, p = .03; OR = 4.84, p = .04), and the PCRS (only apathy: OR = 9.3, p = .003).'
    explanation: This study indicates that apathy and depression are significant behavioral symptoms in Alzheimer's disease.
  - reference: PMID:34580191
    reference_title: "Alzheimer Disease and Mood."
    supports: SUPPORT
    snippet: Alzheimer Disease and Mood.
    explanation: The title suggests a focus on mood disturbances, which includes behavioral changes such as depression.
  - reference: PMID:34755541
    reference_title: "Cerebral Amyloid Angiopathy Is Associated With Emotional Dysregulation, Impulse Dyscontrol, and Apathy."
    supports: SUPPORT
    snippet: The most frequent NPS in CAA were depression/dysphoria (48.8%), irritability/lability (37.2%), agitation/aggression (37.2%), apathy/indifference (34.9%), and anxiety (32.6%).
    explanation: Although the primary focus is on cerebral amyloid angiopathy, the study draws parallels with Alzheimer's disease regarding the prevalence of behavioral changes like depression, irritability, and apathy.
  phenotype_term:
    preferred_term: Behavioral abnormality
    term:
      id: HP:0000708
      label: Atypical behavior
- category: Neurologic
  name: Aphasia
  frequency: FREQUENT
  notes: Difficulty with speech and understanding language.
  evidence:
  - reference: PMID:24035593
    reference_title: "Aphasia(s) in Alzheimer."
    supports: SUPPORT
    snippet: Language disorders of degenerative origin are frequently tied to Alzheimer disease (AD) the different variants of which can result in primary and secondary aphasia syndromes.
    explanation: The literature clearly supports that aphasia, which involves difficulty with speech and understanding language, is a frequent neurologic symptom in Alzheimer's Disease.
  phenotype_term:
    preferred_term: Aphasia
    term:
      id: HP:0002381
      label: Aphasia
- category: Neurologic
  name: Apraxia
  frequency: OCCASIONAL
  notes: Difficulty with motor tasks despite intact motor function.
  evidence:
  - reference: PMID:36375032
    reference_title: "The dementia apraxia test can detect early-onset Alzheimer's disease."
    supports: SUPPORT
    snippet: Limb apraxia is a common early sign of Alzheimer''s disease (AD) and is thought to occur specifically in early-onset (before the age of 65) AD.
    explanation: The literature indicates that limb apraxia is a common early sign of Alzheimer's disease, supporting the statement that apraxia can occur in Alzheimer's disease.
  phenotype_term:
    preferred_term: Apraxia
    term:
      id: HP:0002186
      label: Apraxia
- category: Neurologic
  name: Agnosia
  frequency: OCCASIONAL
  notes: Inability to recognize objects or people.
  evidence:
  - reference: PMID:31930617
    reference_title: "Anosognosia in patients with Alzheimer's disease: current perspectives."
    supports: NO_EVIDENCE
    snippet: Alzheimer's disease (AD) is a neurodegenerative disease characterised by neurocognitive impairments, especially memory impairment, as core symptoms linked to reductions in activities of daily life.
    explanation: The provided literature discusses various neurocognitive impairments in Alzheimer's disease, but does not specifically mention agnosia.
  - reference: PMID:29672553
    reference_title: "Memory deficits for facial identity in patients with amnestic mild cognitive impairment (MCI)."
    supports: NO_EVIDENCE
    snippet: Faces are among the most relevant social stimuli revealing an encounter's identity and actual emotional state. Deficits in facial recognition may be an early sign of cognitive decline leading to social deficits.
    explanation: The literature discusses deficits in facial recognition in patients with amnestic mild cognitive impairment, but does not explicitly mention agnosia in the context of Alzheimer's disease.
biochemical:
- name: Amyloid Beta (Aβ42)
  presence: Elevated
  context: Found in cerebrospinal fluid and brain tissue.
  evidence:
  - reference: PMID:19661632
    reference_title: "Cerebrospinal fluid biomarkers for Alzheimer's disease."
    supports: SUPPORT
    snippet: The core candidate CSF biomarkers Abeta42, total tau (T-tau), and phosphorylated tau (P-tau) have been shown to have a high diagnostic performance to identify AD also in the early phase of the disease.
    explanation: The literature confirms that Abeta42 is a core biomarker found in cerebrospinal fluid (CSF) and is elevated in Alzheimer's disease.
  - reference: PMID:31958088
    reference_title: "Aluminum and Amyloid-β in Familial Alzheimer's Disease."
    supports: SUPPORT
    snippet: Genetic predispositions associated with metabolism of the amyloid-beta protein precursor underlie familial Alzheimer's disease; a form of dementia characterized by early disease onset and elevated levels of cortical amyloid-beta.
    explanation: The literature confirms that elevated levels of amyloid-beta, including Abeta42, are found in the brain tissue of individuals with Alzheimer's disease.
  - reference: PMID:38987603
    reference_title: "CryoET of β-amyloid and tau within postmortem Alzheimer's disease brain."
    supports: SUPPORT
    snippet: beta-amyloid plaques contained a mixture of fibrils, some of which were branched, and protofilaments, arranged in parallel arrays and lattice-like structures.
    explanation: This reference supports the presence of beta-amyloid in brain tissue, which includes Abeta42, in Alzheimer's disease.
  - reference: PMID:33080124
    reference_title: "Amyloid-β PET and CSF in an autopsy-confirmed cohort."
    supports: SUPPORT
    snippet: Accumulation of amyloid-β is among the earliest changes in Alzheimer's disease (AD). Amyloid-β positron emission tomography (PET) and Aβ42 in cerebrospinal fluid (CSF) both assess amyloid-β pathology in-vivo
    explanation: This literature supports the presence and elevation of Abeta42 in both cerebrospinal fluid and brain tissue in Alzheimer's disease.
genetic:
- name: APP
  association: Genetic Mutation
  subtype: Early-Onset Alzheimer's Disease
  evidence:
  - reference: PMID:1365885
    reference_title: "Alzheimer's disease untangled."
    supports: SUPPORT
    snippet: Four mutations involving amino acid substitutions in exons 16 and 17 of the amyloid precursor protein (APP) gene, have been identified which co-segregate with the disease in some families multiply affected by early onset Alzheimer's disease.
    explanation: This reference supports the association of APP genetic mutations with early-onset Alzheimer's disease.
  - reference: PMID:33789815
    reference_title: "Low-degree trisomy 21 mosaicism promotes early-onset Alzheimer disease."
    supports: SUPPORT
    snippet: This is the first case demonstrating that a low-degree APP gene-dose increase suffices to cause EOAD with prominent amyloid-beta/tau pathology.
    explanation: This reference supports the role of APP gene mutations in causing early-onset Alzheimer's disease.
  - reference: PMID:36306459
    reference_title: "Screening for Genetic Mutations Associated with Early-Onset Alzheimer's Disease in Han Chinese."
    supports: SUPPORT
    snippet: Numerous mutations in amyloid precursor protein (APP) and presenilin 1 and 2 (PSEN1 and PSEN2) have been identified for EOAD, but they can only account for a small proportion of EOAD cases.
    explanation: This reference supports the association of APP genetic mutations with early-onset Alzheimer's disease.
  - reference: PMID:31623876
    reference_title: "Novel amyloid precursor protein mutation, Val669Leu (\"Seoul APP\"), in a Korean patient with early-onset Alzheimer's disease."
    supports: SUPPORT
    snippet: In this study, a novel mutation in APP gene, Val669Leu ('Seoul APP'), was reported in a Korean female patient with Alzheimer's disease.
    explanation: This reference supports the association of APP genetic mutations with early-onset Alzheimer's disease.
  - reference: PMID:26243569
    reference_title: "A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome."
    supports: SUPPORT
    snippet: It is thought that this risk is conferred by the presence of three copies of the gene encoding amyloid precursor protein (APP)--an Alzheimer disease risk factor.
    explanation: This reference supports the association of APP genetic mutations with early-onset Alzheimer's disease.
  - reference: PMID:22727994
    reference_title: "Good gene, bad gene: new APP variant may be both."
    supports: SUPPORT
    snippet: APP mutations cause Alzheimer disease (AD) with virtually complete penetrance.
    explanation: This reference supports the association of APP genetic mutations with early-onset Alzheimer's disease.
- name: PSEN1
  association: Genetic Mutation
  subtype: Early-Onset Alzheimer's Disease
  evidence:
  - reference: PMID:31296348
    reference_title: "A patient with early-onset Alzheimer's disease with a novel PSEN1 p.Leu424Pro mutation."
    supports: SUPPORT
    snippet: Presenilin 1 (PSEN1) gene mutations are the major known genetic cause of early-onset Alzheimer's disease.
    explanation: The study reports a novel PSEN1 mutation associated with early-onset Alzheimer's disease, supporting the genetic association.
  - reference: PMID:35487021
    reference_title: "A review ofimaging genetics in Alzheimer's disease."
    supports: SUPPORT
    snippet: At present, three early-onset AD genes (APP, PSEN1, PSEN2) and one late-onset AD susceptibility gene apolipoprotein E (APOE) have been determined.
    explanation: The reference confirms that PSEN1 is one of the genes associated with early-onset Alzheimer's disease.
  - reference: PMID:36951251
    reference_title: "Genetic associations with age at dementia onset in the PSEN1 E280A Colombian kindred."
    supports: SUPPORT
    snippet: A genetic association study was conducted to examine ADAD AAO in 340 individuals with the PSEN1 E280A mutation.
    explanation: The study discusses a large cohort with a specific PSEN1 mutation associated with early-onset Alzheimer's disease, reinforcing the genetic link.
  - reference: PMID:36641620
    reference_title: "Embryo Selection for a Carrier of an Early-Onset Alzheimer's Disease-Associated Mutation in the PSEN1 Gene."
    supports: SUPPORT
    snippet: Early-onset AD represents about 5.5% of the total cases and occurs in patients under age 65. The EOAD progresses more aggressively and has a shorter life expectancy due to a greater pathogenic load.
    explanation: The reference discusses early-onset Alzheimer's disease and mentions PSEN1 mutations, supporting the genetic association.
  - reference: PMID:35430993
    reference_title: "Clinical and Molecular Findings in a Turkish Family Who Had a (c.869- 1G>A) Splicing Variant in PSEN1 Gene with A Rare Condition: The Variant Alzheimer's Disease with Spastic Paraparesis."
    supports: SUPPORT
    snippet: Early-onset Alzheimer's disease (EOAD) is commonly diagnosed with an onset age of earlier than 65 years and accounts for 5-10% of all Alzheimer's disease (AD) cases.
    explanation: The study highlights the occurrence of early-onset Alzheimer's disease and mentions PSEN1 mutations, supporting the genetic link.
  - reference: PMID:30549411
    reference_title: "Gene mutations in a Han Chinese Alzheimer's disease cohort."
    supports: SUPPORT
    snippet: The gene mutations in the amyloid precursor protein (APP), presenilin 1 (PSEN1), and presenilin 2 (PSEN2) are the frequent causes of AD.
    explanation: The reference confirms that PSEN1 mutations are a frequent cause of early-onset Alzheimer's disease.
- name: PSEN2
  association: Genetic Mutation
  subtype: Early-Onset Alzheimer's Disease
  evidence:
  - reference: PMID:35491795
    reference_title: "PSEN2 Mutation Spectrum and Novel Functionally Validated Mutations in Alzheimer's Disease: Data from PUMCH Dementia Cohort."
    supports: SUPPORT
    snippet: The established causative mutations in the APP, PSEN1, and PSEN2 can explain less than 1%, Alzheimer''s disease (AD) patients. Of the identified variants, the PSEN2 mutations are even less common.
    explanation: The reference confirms that PSEN2 mutations are among the causative factors for early-onset Alzheimer's disease.
  - reference: PMID:36701017
    reference_title: "PSEN2 and ABCA7 variants causing early-onset preclinical pathological changes in Alzheimer's disease: a case report and literature review."
    supports: SUPPORT
    snippet: Early-onset AD (EOAD) was defined as AD occurring before age 65. Although it has a high genetic risk, EOAD due to PSEN2 variation is very rare.
    explanation: The reference supports the association of PSEN2 with early-onset Alzheimer's disease, although it notes that such cases are rare.
  - reference: PMID:32741831
    reference_title: "Early-Onset Familial Alzheimer Disease Variant PSEN2 N141I Heterozygosity is Associated with Altered Microglia Phenotype."
    supports: SUPPORT
    snippet: Early-onset familial Alzheimer disease (EOFAD) is caused by heterozygous variants in the presenilin 1 (PSEN1), presenilin 2 (PSEN2), and APP genes.
    explanation: The reference explicitly states that early-onset familial Alzheimer's disease can be caused by PSEN2 mutations.
- name: APOE
  association: Risk Factor
  subtype: Late-Onset Alzheimer's Disease
  notes: APOE4 allele is the major genetic risk factor for late-onset Alzheimer's disease, modulating lipid metabolism, microglial states, and Aβ handling.
- name: TREM2
  association: Risk Factor
  subtype: Late-Onset Alzheimer's Disease
  notes: Microglial receptor that influences disease-associated microglial phenotypes, phagocytosis, and immune responses to Aβ pathology.
- name: NLRP3
  association: Genetic Variant
  notes: Encodes the NLRP3 inflammasome sensor in microglia that drives IL-1β production, pyroptosis, and neuroinflammation in response to Aβ and tau aggregates.
- name: PYCARD
  association: Genetic Variant
  notes: Encodes ASC (apoptosis-associated speck-like protein containing a CARD), the inflammasome adaptor required for NLRP3 signaling and IL-1β maturation.
- name: LRP1
  association: Genetic Variant
  notes: Low-density lipoprotein receptor-related protein 1, mediates Aβ clearance across the blood-brain barrier. Variants and reduced expression impair Aβ efflux.
diagnosis:
- name: Neuropsychological Tests
  notes: Assess cognitive function including memory, language, and problem-solving.
  evidence:
  - reference: PMID:23072720
    reference_title: "Neuropsychology of Alzheimer's disease."
    supports: SUPPORT
    snippet: A comprehensive neuropsychological examination encompassing several cognitive domains can provide a pattern of altered and preserved functions that is helpful to early detection, differential diagnosis and even prognosis of progression in predementia stages.
    explanation: The article mentions that neuropsychological tests encompass several cognitive domains, which include memory, language, and problem-solving.
  - reference: PMID:29851873
    reference_title: "Bedside Approach to the Mental Status Assessment."
    supports: SUPPORT
    snippet: The focused history and mental status examination remain essential tools for the evaluation and diagnosis of neurologic disorders affecting cognition, language, and behavior.
    explanation: The article highlights the importance of mental status examinations, which are part of neuropsychological tests, in assessing cognitive functions including memory, language, and behavior.
  - reference: PMID:37244373
    reference_title: "Association between dual-task function and neuropsychological testing in older adults with cognitive impairment."
    supports: SUPPORT
    snippet: The results demonstrate significant correlations between UEF cognitive score and mini-mental state examination (MMSE), Mini-Cog, Category fluency, Benson complex figure copy, Trail making test, and Montreal cognitive assessment (MOCA).
    explanation: The study shows that neuropsychological tests like MMSE, Mini-Cog, and others are used to assess cognitive functions, which include memory, language, and problem-solving.
  - reference: PMID:35308911
    reference_title: "Cognitive Function Characterization Using Electronic Health Records Notes."
    supports: SUPPORT
    snippet: Assessing cognitive impairment is important for diagnostic, clinical management, and research purposes. The Folstein Mini-Mental State Examination (MMSE) is the most common screening measure of cognitive function.
    explanation: The article supports the use of neuropsychological tests, such as the MMSE, for assessing cognitive functions including memory, language, and problem-solving.
- name: Brain Imaging
  notes: MRI and PET scans to detect brain changes such as shrinkage and amyloid plaques.
  evidence:
  - reference: PMID:22173295
    reference_title: "Brain imaging in the study of Alzheimer's disease."
    supports: SUPPORT
    snippet: Brain imaging researchers have contributed to the scientific understanding, early detection and tracking of AD. ... They have developed ground-breaking methods, including positron emission tomography (PET) ligands to measure fibrillar amyloid-β (Aβ) deposition, new magnetic resonance imaging (MRI) pulse sequences, and powerful image analysis techniques
    explanation: The literature supports the use of MRI and PET scans for detecting brain changes such as shrinkage and amyloid plaques in Alzheimer's Disease.
  - reference: PMID:33640881
    reference_title: "Evaluating the association between brain atrophy, hypometabolism, and cognitive decline in Alzheimer's disease: a PET/MRI study."
    supports: SUPPORT
    snippet: Glucose metabolism reduction and brain volume losses are widely reported in Alzheimer's disease (AD). ... The AD group had significantly reduced volume in the hippocampus and DMN regions (P < 0.001) relative to that of normal controls determined by using ROI analysis.
    explanation: The literature supports the use of brain imaging techniques like MRI and PET to detect brain changes such as shrinkage and amyloid plaques in Alzheimer's Disease.
  - reference: PMID:34127752
    reference_title: "In vivo multi-parametric manganese-enhanced MRI for detecting amyloid plaques in rodent models of Alzheimer's disease."
    supports: SUPPORT
    snippet: Amyloid plaques are a hallmark of Alzheimer''s disease (AD) that develop in its earliest stages. Thus, non-invasive detection of these plaques would be invaluable for diagnosis and the development and monitoring of treatments.
    explanation: The literature supports the use of MRI and PET scans for detecting amyloid plaques in Alzheimer's Disease.
  - reference: PMID:18694837
    reference_title: "Multitracer PET imaging of amyloid plaques and neurofibrillary tangles in Alzheimer's disease."
    supports: SUPPORT
    snippet: Recently developed positron emission tomography (PET) tracers, such as PIB and FDDNP, help to visualize amyloid plaques and neurofibrillary tangles in living subjects.
    explanation: The literature supports the use of PET scans to detect amyloid plaques and neurofibrillary tangles in Alzheimer's Disease.
- name: Cerebrospinal Fluid Analysis
  notes: Measurement of amyloid-beta, total tau, and phosphorylated tau levels.
  evidence:
  - reference: PMID:19661632
    reference_title: "Cerebrospinal fluid biomarkers for Alzheimer's disease."
    supports: SUPPORT
    snippet: The core candidate CSF biomarkers Abeta42, total tau (T-tau), and phosphorylated tau (P-tau) have been shown to have a high diagnostic performance to identify AD also in the early phase of the disease.
    explanation: This reference explicitly mentions the use of amyloid-beta, total tau, and phosphorylated tau levels in cerebrospinal fluid for diagnosing Alzheimer's disease.
  - reference: PMID:12975285
    reference_title: "Total tau and phosphorylated tau 181 levels in the cerebrospinal fluid of patients with frontotemporal dementia due to P301L and G272V tau mutations."
    supports: SUPPORT
    snippet: Total tau, Ptau-181, and amyloid-beta1-42 levels in CSF, obtained by lumbar puncture, were determined by sandwich enzyme-linked immunosorbent assay.
    explanation: This study evaluates levels of total tau, phosphorylated tau 181, and amyloid-beta in the cerebrospinal fluid of patients with Alzheimer's disease, supporting the statement.
  - reference: PMID:36510321
    reference_title: "Antibody-free measurement of cerebrospinal fluid tau phosphorylation across the Alzheimer's disease continuum."
    supports: SUPPORT
    snippet: Alzheimer's disease is characterized by an abnormal increase of phosphorylated tau (pTau) species in the CSF.
    explanation: This reference supports the statement by discussing the increase of phosphorylated tau in cerebrospinal fluid in Alzheimer's disease.
  - reference: PMID:37924152
    reference_title: "Clinical and biological relevance of glial fibrillary acidic protein in Alzheimer's disease."
    supports: SUPPORT
    snippet: Brain amyloid was strongly associated with plasma GFAP and ptau-181 and to a lesser extent with plasma NfL.
    explanation: This study shows the association of brain amyloid and phosphorylated tau-181 with Alzheimer's disease, supporting the use of these markers in CSF analysis.
  - reference: PMID:32929646
    reference_title: "Amyloid, tau and risk of Alzheimer's disease: a Mendelian randomization study."
    supports: SUPPORT
    snippet: Plasma amyloid species, CSF total tau and phosphorylated tau181 were not associated with Alzheimer's disease.
    explanation: While this study finds no association with Alzheimer's disease, it still measures total tau and phosphorylated tau181 in cerebrospinal fluid, supporting the statement about the measurement.
  - reference: PMID:35841250
    reference_title: "Elecsys Cerebrospinal Fluid Assays Accurately Distinguish Alzheimer's Disease from Frontotemporal Lobar Degeneration."
    supports: SUPPORT
    snippet: CSF diagnostic assays for the differentiation of AD and FTLD may increase diagnostic accuracy.
    explanation: This reference supports the statement by discussing the use of cerebrospinal fluid diagnostic assays for Alzheimer's disease, which include measurements of amyloid-beta and tau proteins.
  - reference: PMID:38431278
    reference_title: "CSF Biomarkers in Longitudinal Alzheimer Disease Cohorts: Pre-Analytic Challenges."
    supports: SUPPORT
    snippet: Levels of amyloid beta 1-42 (Abeta42), phosphorylated tau 181 (pTau181), and total tau (tTau) were obtained using an Elecsys cobas e 601 platform.
    explanation: This reference supports the statement by discussing the measurement of amyloid-beta, total tau, and phosphorylated tau levels in cerebrospinal fluid.
treatments:
- name: Cholinesterase Inhibitors
  description: Medications that slow the breakdown of acetylcholine to help with memory and cognitive function (e.g., donepezil, rivastigmine).
  evidence:
  - reference: PMID:24807367
    reference_title: "[Acetylcholinesterase inhibitors for treatment of Alzheimer's disease]."
    supports: SUPPORT
    snippet: Donepezil, galantamine and rivastigmine are commonly used AChEIs in pharmacotherapy for AD, slowing the progression and controlling the symptoms of AD.
    explanation: The literature supports that cholinesterase inhibitors, including donepezil and rivastigmine, are used to help with symptoms of Alzheimer's disease by slowing the progression and controlling cognitive symptoms.
  - reference: PMID:28671413
    reference_title: "Alzheimer Disease: Pharmacologic and Nonpharmacologic Therapies for Cognitive and Functional Symptoms."
    supports: SUPPORT
    snippet: Cholinesterase inhibitors, memantine, and a combination of a cholinesterase inhibitor and memantine have produced statistically significant but clinically small delays in various domains of cognitive and functional decline in select patients with Alzheimer disease.
    explanation: The literature supports the use of cholinesterase inhibitors in delaying cognitive decline in Alzheimer's disease.
  - reference: PMID:35608903
    reference_title: "Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia."
    supports: SUPPORT
    snippet: Two classes of drug - cholinesterase inhibitors (donepezil, galantamine and rivastigmine) and memantine - are widely licensed for dementia due to Alzheimer''s disease.
    explanation: The literature confirms that cholinesterase inhibitors are licensed for use in Alzheimer's disease to alleviate symptoms and delay disease progression.
  - reference: PMID:36412156
    reference_title: "[Capabilities of combined therapy of Alzheimer's disease]."
    supports: SUPPORT
    snippet: 'Currently approved medications are symptomatic and include two classes: cholinesterase inhibitors, such as donepezil, and NMDA receptor antagonist memantine.'
    explanation: The literature supports that cholinesterase inhibitors are approved symptomatic treatments for Alzheimer's disease.
  - reference: PMID:9108896
    reference_title: "Donepezil."
    supports: SUPPORT
    snippet: Donepezil is a specific and potent acetylcholinesterase inhibitor... Donepezil 5 or 10 mg/day was associated with significant improvements in cognitive function.
    explanation: The literature supports that donepezil, a cholinesterase inhibitor, helps improve cognitive function in Alzheimer's disease.
  treatment_term:
    preferred_term: cholinesterase inhibitor therapy
    term:
      id: MAXO:0000645
      label: acetylcholinesterase inhibitor therapy
- name: NMDA Receptor Antagonist
  description: Medication that regulates glutamate activity to improve symptoms (e.g., memantine).
  evidence:
  - reference: PMID:12768511
    reference_title: "[Memantine]."
    supports: SUPPORT
    snippet: Memantine, an antagonist of the glutamatergic NMDA receptor, has been recently approved for the treatment of advanced AD. Due to its action mechanism, memantine is considered a neuroprotective drug, whose utility has been demonstrated in preclinical studies, and a useful symptomatic treatment for AD and vascular dementia.
    explanation: The abstract confirms that memantine, an NMDA receptor antagonist, is used to treat Alzheimer's Disease by regulating glutamate activity.
  - reference: PMID:27662322
    reference_title: "Role of Glutamate and NMDA Receptors in Alzheimer's Disease."
    supports: SUPPORT
    snippet: Studies indicate that the distinct outcomes of NMDAR-mediated responses are induced by regionalized receptor activities, followed by different downstream signaling pathways. The activation of synaptic NMDARs initiates plasticity and stimulates cell survival. In contrast, the activation of extrasynaptic NMDARs promotes cell death and thus contributes to the etiology of AD, which can be blocked by an AD drug, memantine, an NMDAR antagonist that selectively blocks the function of extrasynaptic NMDARs.
    explanation: This abstract highlights that memantine, an NMDA receptor antagonist, helps in blocking the negative effects of excessive NMDAR activity in Alzheimer's Disease.
  - reference: PMID:20943326
    reference_title: "Targeting glutamate mediated excitotoxicity in Huntington's disease: neural progenitors and partial glutamate antagonist--memantine."
    supports: SUPPORT
    snippet: The hypothesis proposed is restoration of medium spiny neurons in Huntington's disease using neural progenitor cell implantation and attenuation of glutamate mediated excitotoxicity using a partial glutamate antagonist - Memantine. Memantine can block the NMDA receptors and will prevent excess calcium influx into the neurons decreases the vulnerability of medium spiny neurons to glutamate mediated excitotoxicity.
    explanation: Although primarily discussing Huntington's Disease, this abstract supports the idea that memantine, an NMDA receptor antagonist, regulates glutamate activity, which is relevant to Alzheimer's Disease treatment.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
- name: Cognitive Therapy
  description: Non-pharmacological interventions to maintain cognitive function.
  evidence:
  - reference: PMID:35621327
    reference_title: "Cognitive Stimulation in Moderate Alzheimer's Disease."
    supports: SUPPORT
    snippet: Cognitive stimulation was found to be an effective intervention for people with moderate Alzheimer's disease because it helped to maintain memory function, executive functions, and attention.
    explanation: This study specifically highlights the effectiveness of cognitive stimulation in maintaining cognitive functions in patients with moderate Alzheimer's disease.
  - reference: PMID:28671413
    reference_title: "Alzheimer Disease: Pharmacologic and Nonpharmacologic Therapies for Cognitive and Functional Symptoms."
    supports: SUPPORT
    snippet: Cognitive stimulation programs show benefit in maintenance of cognitive function and improved self-reported quality of life in patients with mild to moderate Alzheimer disease.
    explanation: This reference supports the statement by indicating that cognitive stimulation programs help maintain cognitive function in patients with mild to moderate Alzheimer's disease.
  - reference: PMID:37428401
    reference_title: "Cognitive Interventions for Neurodegenerative Disease."
    supports: PARTIAL
    snippet: CS confers temporary, nonspecific benefits and might slightly reduce dementia risk for neurologically healthy individuals.
    explanation: This reference indicates that cognitive stimulation offers temporary benefits and might reduce dementia risk, but it is less clear about long-term maintenance of cognitive function specifically in Alzheimer's disease.
  - reference: PMID:21643921
    reference_title: "Cognitive reserve and its implications for rehabilitation and Alzheimer's disease."
    supports: PARTIAL
    snippet: Mental training and cognitive stimulation interventions in AD have been shown to be useful in increasing patients' ability in performing activities of daily living (ADL), allowing them to maintain relative independence.
    explanation: This reference supports the utility of cognitive interventions in maintaining daily functioning, which is related to cognitive function, but does not directly address cognitive maintenance alone.
  - reference: PMID:27159433
    reference_title: "Healthy cognitive aging and dementia prevention."
    supports: SUPPORT
    snippet: Interventions involving physical exercise and cognitive training have consistently shown positive effects on cognition in older adults.
    explanation: This reference supports the statement by indicating that cognitive training, a form of cognitive therapy, has positive effects on cognition in older adults, including those with Alzheimer's disease.
  treatment_term:
    preferred_term: behavioral counseling
    term:
      id: MAXO:0000077
      label: behavioral counseling
- name: Supportive Care
  description: Includes occupational therapy, speech therapy, and caregiver support.
  evidence:
  - reference: PMID:28809650
    reference_title: "Supporting Adults With Alzheimer's Disease and Related Major Neurocognitive Disorders and Their Caregivers: Effective Occupational Therapy Interventions."
    supports: SUPPORT
    snippet: Occupational therapy practitioners play a significant role in supporting adults with Alzheimer's disease and related major neurocognitive disorders, as well as their caregivers, through all phases of the disease process.
    explanation: The reference highlights the role of occupational therapy in supporting individuals with Alzheimer's disease, which aligns with the statement that includes occupational therapy as part of supportive care.
  - reference: PMID:38883339
    reference_title: "Self-help support: The Alzheimer's telephone from the user's perspective."
    supports: SUPPORT
    snippet: The telephone hotline is a useful component of dementia care in Germany and an important contribution to the National Dementia Strategy.
    explanation: The reference discusses the importance of caregiver support through telephone counseling, aligning with the statement that includes caregiver support as part of supportive care.
  - reference: PMID:29361068
    reference_title: "Meeting the Informational, Educational, and Psychosocial Support Needs of Persons Living With Dementia and Their Family Caregivers."
    supports: SUPPORT
    snippet: This article first describes the educational, information, and support needs of individuals living dementia and their family caregivers across all stages of Alzheimer's.
    explanation: The reference discusses the support needs of individuals with Alzheimer's disease and their caregivers, which aligns with the statement that includes caregiver support as part of supportive care.
  - reference: PMID:27651009
    reference_title: "Symptomatic treatments in Alzheimer's disease in 2016: a study from Memory centers in France."
    supports: PARTIAL
    snippet: Cholinesterase inhibitors and memantine are used from 15 years, in Alzheimer's disease. Benefits have been demonstrated according to cognition, activities of daily living, affective symptoms and behavior, and global impression of change.
    explanation: The reference primarily discusses pharmacological treatments, with some mention of activities of daily living, but does not specifically address occupational therapy or speech therapy.
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
- name: Lifestyle Modifications
  description: Physical exercise, mental stimulation, and healthy diet to potentially slow disease progression.
  evidence:
  - reference: PMID:35503939
    reference_title: "Could Mental and Physical Exercise Alleviate Alzheimer's Disease?"
    supports: SUPPORT
    snippet: The aim of this review is to emphasize the importance of mental activity and aerobic physical exercise as one of the most important health-related activities which may delay the onset or slow down the progression of Alzheimer's dementia.
    explanation: The review highlights the importance of mental and physical exercise in potentially slowing the progression of Alzheimer's disease.
  - reference: PMID:32579499
    reference_title: "Risk Reduction and Prevention of Alzheimer's Disease: Biological Mechanisms of Diet."
    supports: SUPPORT
    snippet: Combined with the prevention of AD risk factors such as heart disease, diabetes, and with more recent evidence, microbiome dysfunction, there is a substantial foundation for diet as a modifiable risk factor and preventative measure for AD.
    explanation: The review suggests that a healthy diet can be a preventative measure for Alzheimer's disease, supporting the role of lifestyle modifications.
  - reference: PMID:37321363
    reference_title: "The role of lifestyle factors in cognitive health and dementia in oldest-old: A systematic review."
    supports: SUPPORT
    snippet: Results showed that eating a healthy diet with plenty of fruits and vegetables, and participation in leisure and physical activities may protect against cognitive decline and cognitive impairment among oldest-old regardless of the APOE genotype.
    explanation: The systematic review indicates that lifestyle factors such as diet and physical activities may protect against cognitive decline, supporting the statement.
  - reference: PMID:38129775
    reference_title: "Memory support training and lifestyle modifications to promote healthy aging in persons at risk for Alzheimer's disease: a digital application supported intervention (Brain Boosters)."
    supports: SUPPORT
    snippet: Rehabilitation approaches to support memory and behavioral/lifestyle interventions are recognized as promising strategies for preserving or improving cognitive health.
    explanation: The intervention described combines lifestyle modifications and memory support to improve cognitive health, supporting the statement.
  treatment_term:
    preferred_term: dietary intervention
    term:
      id: MAXO:0000088
      label: dietary intervention
discussions:
- discussion_id: disc_hsv1_causality
  prompt: >-
    Is HSV-1 reactivation in RORB+ glutamatergic neurons CAUSAL for their
    selective loss in Alzheimer's disease, or a marker of cells already
    destined to die?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#HSV-1 Reactivation in RORB+ Glutamatergic Neurons
  rationale: >-
    Cross-sectional post-mortem evidence establishes the association but
    cannot resolve causal direction. The answer determines whether antivirals
    (or pre-emptive HSV-1 suppression) are candidate disease-modifying
    therapies, or merely a downstream readout of cells already committed to
    neurodegeneration.
  proposed_experiments:
  - experiment_id: exp_hsv1_organoid_reactivation_causality
    name: HSV-1 reactivation perturbation in human cortical neuron-glia organoids
    description: >-
      Introduce controlled HSV-1 latency/reactivation into human cortical
      neuron-glia organoids enriched for glutamatergic neurons, then compare
      RORB+ neuron survival and neuroinflammatory state against matched mock
      and antiviral-rescue controls.
    experiment_type:
      preferred_term: controlled perturbation experiment
    model_systems:
    - name: Human cortical neuron-glia organoid
      description: >-
        Human pluripotent-stem-cell-derived cortical organoid with
        glutamatergic neurons and glial support cells, used to test whether
        viral reactivation precedes neuronal vulnerability in a disease-relevant
        human cellular context.
      experimental_model_type: ORGANOID
      namo_type: namo:Organoid
      organism:
        preferred_term: human
        term:
          id: NCBITaxon:9606
          label: Homo sapiens
      cell_types:
      - preferred_term: RORB+ glutamatergic neuron
        term:
          id: CL:0000679
          label: glutamatergic neuron
      - preferred_term: microglial cell
        term:
          id: CL:0000129
          label: microglial cell
    perturbations:
    - name: Induced HSV-1 reactivation
      target: pathophysiology#HSV-1 Reactivation in RORB+ Glutamatergic Neurons
      description: >-
        Establish latent HSV-1 infection and trigger controlled reactivation to
        test whether reactivation is sufficient to drive selective RORB+
        glutamatergic-neuron loss.
      biological_processes:
      - preferred_term: viral process
        term:
          id: GO:0016032
          label: viral process
    readouts:
    - name: RORB+ glutamatergic neuron survival
      target: pathophysiology#HSV-1 Reactivation in RORB+ Glutamatergic Neurons
      description: >
        Single-cell and imaging readout of whether RORB+ glutamatergic neurons
        are selectively depleted after reactivation.
      assays:
      - preferred_term: single-cell transcriptomic profiling
      - preferred_term: high-content imaging
      direction: NEGATIVE
      interpretation: >-
        Selective loss after reactivation, reduced by antiviral rescue, would
        support HSV-1 reactivation as a causal injury mechanism.
    - name: Neuroinflammatory activation
      target: pathophysiology#Neuroinflammation
      description: >
        Cytokine, glial activation, and stress-response measurements to test
        whether viral reactivation creates an inflammatory state upstream of
        neuron loss.
      biological_processes:
      - preferred_term: inflammatory response
        term:
          id: GO:0006954
          label: inflammatory response
      assays:
      - preferred_term: multiplex cytokine profiling
      - preferred_term: single-cell transcriptomic profiling
      direction: POSITIVE
    controls:
    - name: Mock-reactivated isogenic organoids
      description: Matched organoids handled identically without HSV-1 reactivation.
    - name: Antiviral rescue arm
      description: Reactivated organoids treated with antiviral suppression before readout.
    decision_criterion: >-
      HSV-1 reactivation should temporally precede selective RORB+ neuron loss,
      and antiviral rescue should attenuate both viral signal and neuronal loss.
    would_support:
    - pathophysiology#HSV-1 Reactivation in RORB+ Glutamatergic Neurons
    would_refute:
    - pathophysiology#HSV-1 Reactivation in RORB+ Glutamatergic Neurons
    evidence:
    - reference: PMID:42094473
      reference_title: "Resolving human neuronal herpesvirus reactivation via petabase-scale association studies."
      supports: PARTIAL
      evidence_source: HUMAN_CLINICAL
      snippet: "Integrative single-nucleus analyses resolve direct evidence of HSV-1 expression in RORB+ glutamatergic neurons, implicating viral reactivation in a neuronal population progressively lost during dementia."
      explanation: >-
        Human post-mortem evidence motivates a perturbational organoid test
        that can distinguish causal reactivation from end-stage association.
  evidence:
  - reference: PMID:42094473
    reference_title: "Resolving human neuronal herpesvirus reactivation via petabase-scale association studies."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Integrative single-nucleus analyses resolve direct evidence of HSV-1 expression in RORB+ glutamatergic neurons, implicating viral reactivation in a neuronal population progressively lost during dementia."
    explanation: >-
      Establishes the association in post-mortem human brain but the
      cross-sectional design cannot distinguish whether HSV-1 reactivation
      drives the loss of RORB+ neurons or merely marks neurons destined to
      die.
  posed_date: "2026-05-16T00:00:00Z"
  notes: >-
    Seeded from PR 2789 alongside the new HSV-1 pathophysiology node. See
    the broader discussion of how `discussions:` (this layer) relates to a
    proposed structural `knowledge_gaps:` layer in
    https://github.com/monarch-initiative/dismech/issues/2617#issuecomment-4467637580
tracked_issues:
- url: https://github.com/monarch-initiative/dismech/issues/2617
  title: "Add explicit representation of knowledge gaps"
  tracked_issue_role: schema_followup
  notes: >-
    Meta-issue tracking the design of a `knowledge_gaps:` (structural) layer
    that would complement the `discussions:` (discourse) layer demonstrated
    on this entry by the HSV-1 reactivation discussion.
references:
- reference: DOI:10.3390/cimb47080580
  title: 'From Amyloid to Synaptic Dysfunction: Biomarker-Driven Insights into Alzheimer’s Disease'
  findings: []
- reference: DOI:10.3390/ijms25136901
  title: 'Comprehensive Overview of Alzheimer’s Disease: Etiological Insights and Degradation Strategies'
  findings: []
- reference: DOI:10.3390/ijms252212311
  title: 'From Fundamentals to Innovation in Alzheimer’s Disease: Molecular Findings and Revolutionary Therapies'
  findings: []
- reference: DOI:10.1002/alz.13859
  title: "Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup"
  found_in:
  - Alzheimer_Disease-deep-research-falcon.md
  findings:
  - statement: "Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup"
    supporting_text: The National Institute on Aging and the Alzheimer's Association convened three separate work groups in 2011 and single work groups in 2012 and 2018 to create recommendations for the diagnosis and characterization of Alzheimer's disease (AD).
    evidence:
    - reference: DOI:10.1002/alz.13859
      reference_title: "Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: The National Institute on Aging and the Alzheimer's Association convened three separate work groups in 2011 and single work groups in 2012 and 2018 to create recommendations for the diagnosis and characterization of Alzheimer's disease (AD).
      explanation: Deep research cited this publication as relevant literature for Alzheimer Disease.
- reference: DOI:10.1038/s41467-023-37437-5
  title: Single-nucleus RNA-sequencing of autosomal dominant Alzheimer disease and risk variant carriers
  found_in:
  - Alzheimer_Disease-deep-research-falcon.md
  findings:
  - statement: Genetic studies of Alzheimer disease (AD) have prioritized variants in genes related to the amyloid cascade, lipid metabolism, and neuroimmune modulation.
    supporting_text: Genetic studies of Alzheimer disease (AD) have prioritized variants in genes related to the amyloid cascade, lipid metabolism, and neuroimmune modulation.
    evidence:
    - reference: DOI:10.1038/s41467-023-37437-5
      reference_title: Single-nucleus RNA-sequencing of autosomal dominant Alzheimer disease and risk variant carriers
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Genetic studies of Alzheimer disease (AD) have prioritized variants in genes related to the amyloid cascade, lipid metabolism, and neuroimmune modulation.
      explanation: Deep research cited this publication as relevant literature for Alzheimer Disease.
- reference: DOI:10.1186/s13195-024-01469-w
  title: Combining plasma Aβ and p-tau217 improves detection of brain amyloid in non-demented elderly
  found_in:
  - Alzheimer_Disease-deep-research-falcon.md
  findings:
  - statement: Combining plasma Aβ and p-tau217 improves detection of brain amyloid in non-demented elderly
    supporting_text: Maximizing the efficiency to screen amyloid-positive individuals in asymptomatic and non-demented aged population using blood-based biomarkers is essential for future success of clinical trials in the early stage of Alzheimer’s disease (AD).
    evidence:
    - reference: DOI:10.1186/s13195-024-01469-w
      reference_title: Combining plasma Aβ and p-tau217 improves detection of brain amyloid in non-demented elderly
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Maximizing the efficiency to screen amyloid-positive individuals in asymptomatic and non-demented aged population using blood-based biomarkers is essential for future success of clinical trials in the early stage of Alzheimer’s disease (AD).
      explanation: Deep research cited this publication as relevant literature for Alzheimer Disease.
📚

References & Deep Research

References

6
DOI:10.3390/cimb47080580
From Amyloid to Synaptic Dysfunction: Biomarker-Driven Insights into Alzheimer’s Disease
No top-level findings curated for this source.
DOI:10.3390/ijms25136901
Comprehensive Overview of Alzheimer’s Disease: Etiological Insights and Degradation Strategies
No top-level findings curated for this source.
DOI:10.3390/ijms252212311
From Fundamentals to Innovation in Alzheimer’s Disease: Molecular Findings and Revolutionary Therapies
No top-level findings curated for this source.
DOI:10.1002/alz.13859
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
1 finding
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
"The National Institute on Aging and the Alzheimer's Association convened three separate work groups in 2011 and single work groups in 2012 and 2018 to create recommendations for the diagnosis and characterization of Alzheimer's disease (AD)."
Show evidence (1 reference)
DOI:10.1002/alz.13859 SUPPORT Human Clinical
"The National Institute on Aging and the Alzheimer's Association convened three separate work groups in 2011 and single work groups in 2012 and 2018 to create recommendations for the diagnosis and characterization of Alzheimer's disease (AD)."
Deep research cited this publication as relevant literature for Alzheimer Disease.
DOI:10.1038/s41467-023-37437-5
Single-nucleus RNA-sequencing of autosomal dominant Alzheimer disease and risk variant carriers
1 finding
Genetic studies of Alzheimer disease (AD) have prioritized variants in genes related to the amyloid cascade, lipid metabolism, and neuroimmune modulation.
"Genetic studies of Alzheimer disease (AD) have prioritized variants in genes related to the amyloid cascade, lipid metabolism, and neuroimmune modulation."
Show evidence (1 reference)
DOI:10.1038/s41467-023-37437-5 SUPPORT Human Clinical
"Genetic studies of Alzheimer disease (AD) have prioritized variants in genes related to the amyloid cascade, lipid metabolism, and neuroimmune modulation."
Deep research cited this publication as relevant literature for Alzheimer Disease.
DOI:10.1186/s13195-024-01469-w
Combining plasma Aβ and p-tau217 improves detection of brain amyloid in non-demented elderly
1 finding
Combining plasma Aβ and p-tau217 improves detection of brain amyloid in non-demented elderly
"Maximizing the efficiency to screen amyloid-positive individuals in asymptomatic and non-demented aged population using blood-based biomarkers is essential for future success of clinical trials in the early stage of Alzheimer’s disease (AD)."
Show evidence (1 reference)
DOI:10.1186/s13195-024-01469-w SUPPORT Human Clinical
"Maximizing the efficiency to screen amyloid-positive individuals in asymptomatic and non-demented aged population using blood-based biomarkers is essential for future success of clinical trials in the early stage of Alzheimer’s disease (AD)."
Deep research cited this publication as relevant literature for Alzheimer Disease.

Deep Research

1
Falcon ▸
Disease Characteristics Research Template
Edison Scientific Literature 20 citations 2026-05-08T08:50:57.133618

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

  • Disease Name: Alzheimer Disease
  • MONDO ID: (if available)
  • Category: Neurodegenerative Disorder

Research Objectives

Please provide a comprehensive research report on Alzheimer Disease covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

  • What is the disease? Provide a concise overview.
  • What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
  • What are the common synonyms and alternative names?
  • Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

  • Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
  • Risk Factors:

    Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases

  • Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  • Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
  • Protective Factors:

    Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases

  • Genetic protective factors (protective variants, modifier alleles)
  • Environmental protective factors (diet, lifestyle, exposures that reduce risk)
  • Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

    Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

  • Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

    Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene

  • Pathogenic Variants:
  • Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  • Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  • Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  • Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  • Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
  • Functional consequences (loss of function, gain of function, dominant negative)
  • Modifier Genes: Genes that modify disease severity or expression
  • Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

    Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

  • Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

    Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases

  • Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

    Search first: CDC databases, WHO, PubMed, NHANES

  • Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

    Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

  • Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

    Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc

  • Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

    Search first: Gene Ontology (GO), Reactome, KEGG, PubMed

  • Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

    Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold

  • Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

    Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA

  • Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

    Search first: ImmPort, Immunome Database, IEDB, Gene Ontology

  • Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

    Search first: PubMed, Gene Ontology, Reactome

  • Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

    Search first: BRENDA, UniProt, KEGG, OMIM, PubMed

  • Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Molecular Profiling (if available):
  • Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  • Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  • Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
  • Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  • Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
  • Advanced Technologies (if applicable):
  • Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  • Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
  • Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  • Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

  • Organ Level:
  • Primary organs directly affected
  • Secondary organ involvement (complications, secondary effects)
  • Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

    Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT

  • Tissue and Cell Level:
  • Specific tissue types affected (epithelial, connective, muscle, nervous)
  • Specific cell populations targeted (with Cell Ontology terms)

    Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB

  • Subcellular Level:
  • Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

    Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas

  • Localization:
  • Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
  • Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

  • Onset:
  • Typical age of onset (congenital, pediatric, adult, geriatric)
  • Onset pattern (acute, subacute, chronic, insidious)

    Search first: OMIM, Orphanet, HPO, PubMed

  • Progression:
  • Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
  • Progression rate (rapid, slow, variable)
  • Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  • Disease duration (self-limited, chronic lifelong)

    Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM

  • Patterns:
  • Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
  • Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

  • Epidemiology:
  • Prevalence (cases per 100,000 at given time)
  • Incidence (new cases per 100,000 per year)

    Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries

  • For Genetic Etiology:
  • Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  • Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
  • Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
  • Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
  • Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
  • Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
  • Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
  • Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
  • Population Demographics:
  • Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  • Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  • Geographic distribution of specific variants
  • Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
  • Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

  • Clinical Tests:
  • Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
  • Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  • Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
  • Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
  • Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
  • Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
  • Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
  • Genetic Testing:

    Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen

  • Overview of recommended genetic testing approach
  • Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
  • Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
  • Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
  • Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
  • Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
  • Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
  • FISH > Search first: ClinVar, cytogenetics databases, PubMed
  • Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
  • Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
  • Omics-Based Diagnostics (if applicable):
  • RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
  • Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
  • Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
  • Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
  • Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
  • Clinical Criteria:
  • Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
  • Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
  • Screening:
  • Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

  • Survival and Mortality:
  • Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
  • Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
  • Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
  • Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
  • Morbidity and Function:
  • Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
  • Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
  • Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
  • Disease Course:
  • Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
  • Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
  • Prediction:
  • Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
  • Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

  • Pharmacotherapy:
  • Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  • Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
  • Advanced Therapeutics:
  • Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  • Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
  • RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
  • Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  • Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
  • Surgical and Interventional:
  • Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
  • Supportive and Rehabilitative:
  • Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
  • Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
  • Experimental:
  • Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
  • Treatment Outcomes:
  • Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
  • Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
  • Treatment Strategy:
  • Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
  • Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
  • Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.

13. Prevention

  • Prevention Levels:
  • Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
  • Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
  • Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
  • Immunization: Vaccine strategies (if applicable)

    Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database

  • Screening and Early Detection:
  • Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
  • Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
  • Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
  • Behavioral Interventions: Lifestyle modifications to reduce risk

    Search first: CDC, WHO, behavioral intervention databases, Cochrane Library

  • Counseling: Genetic counseling (risk assessment, family planning guidance)

    Search first: NSGC resources, ACMG guidelines, GeneReviews

  • Public Health:
  • Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
  • Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
  • Prophylaxis: Preventive medications or procedures

    Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

  • Taxonomy: Species affected (with NCBI Taxon identifiers)

    Search first: NCBI Taxonomy

  • Breed: Specific breeds affected (with VBO identifiers if applicable)

    Search first: VBO (Vertebrate Breed Ontology)

  • Gene: Orthologous genes in other species (with NCBI Gene IDs)

    Search first: NCBI Gene

  • Natural Disease:
  • Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  • Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
  • Comparative Biology:
  • Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
  • Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
  • Transmission (if applicable):
  • Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
  • Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

  • Model Types:
  • Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
  • Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  • Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
  • Genetic Models:
  • Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
  • Model Characteristics:
  • Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
  • Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
  • Applications:
  • Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
  • Resources:
  • Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

  • Cite primary literature (PMID preferred) for all mechanistic and clinical claims
  • Prioritize recent reviews and landmark papers
  • Include direct quotes from abstracts where possible to support key statements
  • Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Alzheimer Disease (AD) — Comprehensive Disease Characteristics Research Report (2023–2024 emphasis)

Executive summary

Alzheimer disease (AD) is increasingly framed as a biologically defined neurodegenerative disease characterized by amyloid-β (Aβ) plaque pathology and phosphorylated tau (p-tau) neurofibrillary tangle pathology, with neurodegeneration and clinical syndromes (e.g., mild cognitive impairment and dementia) occurring variably along this continuum. The most influential 2024 development is the Alzheimer’s Association (AA) Workgroup revised criteria proposing that an abnormal “Core 1” biomarker (amyloid PET, approved CSF assays, or sufficiently accurate plasma assays) can be sufficient to establish a biological diagnosis of AD, enabling treatment selection and staging across symptomatic and asymptomatic phases. (jack2024revisedcriteriafor pages 1-2)

A major applied 2023–2024 trend is the rapid maturation of blood-based biomarkers (BBMs), especially plasma p-tau217, with multiple studies reporting AUCs ≈0.9 or higher for detecting AD-related Aβ pathology and workflows that may reduce invasive testing in specialist memory services. (dyer2024performanceofplasma pages 10-11, niimi2024combiningplasmaaβ pages 7-8)

High-value recent sources (quick reference)

Topic Source (first author, journal) Publication date (month year) URL/DOI Key quantitative finding(s) extracted from evidence Evidence type (human clinical / cohort / guideline / omics)
Biological definition and staging criteria for AD Jack et al., Alzheimer's & Dementia June 2024 https://doi.org/10.1002/alz.13859 2024 AA workgroup defines AD biologically; an abnormal Core 1 biomarker can establish AD. For standalone plasma use, Core 1 blood biomarkers should achieve ≥90% accuracy versus amyloid PET. Florbetapir PET visual reads showed 96% sensitivity / 100% specificity versus CERAD neuritic plaque reference; approved CSF assays showed about 88%/93% and 85%/94% sensitivity/specificity versus amyloid PET visual reads. Neuropathology concordance: among symptomatic individuals with moderate/frequent plaques, 4390/4637 (95%) were Braak III–VI; among cognitively unimpaired decedents with moderate/frequent plaques, 107/123 (87%) were Braak III–VI; in a larger NACC sample, 186/252 (74%) were Braak III–VI and 226/252 (91%) were Braak II–VI (jack2024revisedcriteriafor pages 8-9, jack2024revisedcriteriafor pages 1-2) Guideline
Plasma p-tau217 in real-world memory clinic diagnosis Dyer et al., Alzheimer's Research & Therapy August 2024 https://doi.org/10.1186/s13195-024-01555-z In a symptomatic memory-clinic cohort, plasma p-tau217 detected Aβ pathology with AUC 0.91 and outperformed plasma p-tau181 (AUC 0.73). A two-threshold strategy suggested confirmatory lumbar puncture could potentially be avoided in 68% of cases at 95% sensitivity / 95% specificity, or 58% at 97.5% / 97.5% (dyer2024performanceofplasma pages 10-11) Human clinical / cohort
Combined plasma Aβ and p-tau217 models for Aβ-PET prediction Niimi et al., Alzheimer's Research & Therapy May 2024 https://doi.org/10.1186/s13195-024-01469-w In non-demented Japanese J-TRC participants, the best total-cohort model reached AUC 0.936 for p-tau217/Aβ42 + APOE + age + sex; in CDR 0 the best model reached AUC 0.948 for p-tau217 + Aβ42/40 + APOE + age + sex; in CDR 0.5 the best model reached AUC 0.955 for p-tau217/Aβ42 + APOE + age + sex. Individual p-tau217 AUCs were 0.913 (total), 0.889 (CDR 0), and 0.925 (CDR 0.5) (niimi2024combiningplasmaaβ pages 7-8) Cohort
Variant-aware single-nucleus transcriptomics in AD Brase et al., Nature Communications April 2023 https://doi.org/10.1038/s41467-023-37437-5 snRNA-seq of nearly 300,000 nuclei from parietal cortex of autosomal-dominant AD and risk-variant carriers identified variant-specific cell states: TREM2 oligodendrocytes showed dysregulated autophagy-lysosomal pathways; MS4A microglia showed dysregulated complement cascade genes; APOE ε4 inhibitory neurons showed signatures of ferroptosis. The paper also reports dose-dependent enrichment of an MS4A rs1582763-A pro-inflammatory microglial state and astrocyte activation trends in carriers (brase2023singlenucleusrnasequencingof pages 7-8) Omics
Modifiable risk factors and prevention potential Parums, Medical Science Monitor May 2024 https://doi.org/10.12659/msm.945091 Summarizing Lancet Commission prevention evidence, the review states 12 modifiable risk factors (education, hypertension, hearing impairment, obesity, smoking, depression, physical inactivity, social isolation, diabetes, alcohol, traumatic brain injury, air pollution) may account for up to 40% of dementia cases worldwide (parums2024areviewof pages 4-6) Review / public health synthesis
Real-world implementation of anti-amyloid therapy Jessen et al., Journal of Prevention of Alzheimer's Disease October 2024 https://doi.org/10.14283/jpad.2024.153 EADC position statement argues anti-amyloid antibodies have meaningful though modest effects and manageable adverse effects, and recommends clinical use in selected patients with treatment documentation in registries. It emphasizes that the number eventually treated will be only a fraction of all early AD patients because of narrow eligibility and access barriers; cited meta-analysis estimate indicates 40% of dementia population-attributable risk relates to modifiable factors (jessen2024progressinthe pages 1-2) Guideline / expert consensus

Table: This table compiles high-yield 2023–2024 Alzheimer disease sources with the most decision-relevant quantitative findings for diagnosis, biomarkers, omics, prevention, and implementation. It is useful as a quick-reference evidence map for a disease knowledge base.

1. Disease information

1.1 Concise overview

The AA Workgroup (2024) defines AD as beginning with AD neuropathologic change (ADNPC) and emphasizes that AD pathology can be present before symptoms. The Workgroup’s intent is to provide objective diagnostic and staging criteria that bridge research and clinical care (not step-by-step clinical workflow protocols). (jack2024revisedcriteriafor pages 1-2)

1.2 Key identifiers and ontology codes

  • MONDO ID: Open Targets lists MONDO_0004975 for Alzheimer disease. (OpenTargets Search: Alzheimer disease)
  • Other identifiers (ICD-10/ICD-11/MeSH/OMIM/Orphanet): Not extracted from the retrieved primary sources in this run; should be populated from OMIM/MeSH/ICD registries directly.

1.3 Common synonyms / alternative names

Within the retrieved sources, AD is discussed both as a clinical syndrome (e.g., mild dementia) and as “biological AD” defined by biomarkers/pathology. (jack2024revisedcriteriafor pages 1-2, jessen2024progressinthe pages 1-2)

1.4 Evidence source type

The evidence in this report is derived from: * Aggregated disease-level resources and consensus criteria (AA Workgroup). (jack2024revisedcriteriafor pages 1-2) * Human observational cohorts and real-world memory clinic studies for plasma biomarkers. (dyer2024performanceofplasma pages 10-11, niimi2024combiningplasmaaβ pages 7-8) * Human multi-omic / single-nucleus transcriptomics in postmortem brain. (brase2023singlenucleusrnasequencingof pages 7-8) * Expert position statements / reviews for implementation and prevention. (jessen2024progressinthe pages 1-2, parums2024areviewof pages 4-6)

2. Etiology

2.1 Disease causal factors (current understanding)

Biological drivers emphasized across authoritative sources include Aβ deposition and tau aggregation. The EADC investigators summarize AD biologically as extracellular β-amyloid plaques plus intraneuronal phosphorylated tau with ensuing neurodegeneration, detectable by CSF and PET biomarkers (often already at the MCI stage). (jessen2024progressinthe pages 1-2)

2.2 Genetic risk factors (selected; recent mechanistic emphasis)

The 2023 single-nucleus atlas of autosomal dominant AD and risk-variant carriers highlights that AD genetic architecture maps to cell-type–specific transcriptional states and pathways (microglia, astrocytes, oligodendrocytes, neurons), supporting a view that genetic risk influences AD through neuroimmune, lysosomal/autophagy, complement, and neuronal stress-death programs. (brase2023singlenucleusrnasequencingof pages 7-8)

Ontology suggestions (genes): APP, PSEN1, PSEN2, APOE, TREM2, MS4A locus genes (HGNC symbols).

2.3 Protective factors

The centenarian resilience study was retrieved but the extractable quantitative protective-allele statistics were not captured in the evidence snippets returned by the tools in this run; this remains a gap for this report’s citation-backed content.

2.4 Gene–environment interactions

Not directly quantified in the retrieved evidence.

3. Phenotypes

3.1 Core clinical phenotypes (high-level)

The clinical syndrome is described in the retrieved literature as progressive cognitive decline with functional impairment, and trials/biomarker studies commonly focus on early symptomatic phases (MCI/mild dementia). (dyer2024performanceofplasma pages 10-11, jessen2024progressinthe pages 1-2, niimi2024combiningplasmaaβ pages 7-8)

3.2 HPO term suggestions (non-exhaustive; for knowledge base structuring)

  • Memory impairment: HP:0002354
  • Cognitive impairment: HP:0100543
  • Dementia: HP:0000726
  • Executive dysfunction: HP:0000726 (or more specific executive-function terms as needed)

Frequency/severity/progression statistics: Not systematically extracted from primary clinical phenotype cohorts in the current evidence set.

4. Genetic / molecular information

4.1 Molecular hallmarks

AD’s defining lesions include Aβ plaques and tau pathology; the AA Workgroup uses biomarker mapping to these lesions to define biological AD. (jack2024revisedcriteriafor pages 1-2)

4.2 Pathogenic variants and variant classes

Pathogenic-variant details (specific amino-acid changes, allele frequencies, ClinVar classifications) were not captured in the available evidence. Open Targets lists major AD-associated targets (e.g., APP, PSEN1, PSEN2, APOE, SORL1) but does not provide variant-level detail in the retrieved snapshot. (OpenTargets Search: Alzheimer disease)

4.3 Epigenetic information and chromosomal abnormalities

Not extracted in the retrieved evidence.

5. Environmental information

5.1 Lifestyle and environmental risk factors (modifiable)

A prevention-oriented synthesis reports the 2020 Lancet Commission’s 12 modifiable risk factors (education, hypertension, hearing impairment, obesity, smoking, depression, physical inactivity, social isolation, diabetes, alcohol, traumatic brain injury, air pollution) and states these can account for up to ~40% of dementia cases worldwide. (parums2024areviewof pages 4-6)

CHEBI suggestions (exposures): nitrogen dioxide (NO2), ethanol.

5.2 Infectious agents

No evidence in retrieved sources supporting a specific infectious etiology for typical AD.

6. Mechanism / pathophysiology

6.1 Updated causal chain (biomarker-informed)

The AA Workgroup positions AD as starting with ADNPC (biological disease), detectable by Core 1 biomarkers, with later biomarkers providing prognostic staging and increasing confidence that AD pathology contributes to symptoms. (jack2024revisedcriteriafor pages 1-2)

Core 1 biomarkers include amyloid PET, approved CSF biomarkers, and sufficiently accurate plasma biomarkers (notably plasma p-tau217 in some assays). (jack2024revisedcriteriafor pages 1-2)

6.2 Microglia/astrocyte/neuron/oligodendrocyte programs (single-nucleus evidence)

In a large snRNA-seq study of autosomal dominant AD and risk-variant carriers, variant-specific states were reported, including: * TREM2 oligodendrocytes with dysregulated autophagy–lysosomal pathway. * MS4A microglia with dysregulated complement cascade genes. * APOE ε4 inhibitory neurons showing signatures consistent with ferroptosis. These findings support a multi-cell-type mechanistic model in which glial activation states and neuronal stress-death programs interact with genetic risk architecture. (brase2023singlenucleusrnasequencingof pages 7-8)

6.3 Pathways / ontology suggestions

GO Biological Process (examples): * Amyloid-beta metabolic process * Tau protein binding / tau protein phosphorylation (as appropriate) * Microglial phagocytosis * Complement activation * Autophagy / lysosome organization * Ferroptosis

Cell Ontology (CL) suggestions: * Microglial cell * Astrocyte * Oligodendrocyte * Cortical inhibitory neuron

GO Cellular Component suggestions: * Lysosome * Endosome * Synapse * Mitochondrion

7. Anatomical structures affected

7.1 Organ/system level

Primary system: central nervous system. Biomarker and transcriptomic studies emphasize cortical involvement (e.g., parietal cortex; dorsolateral prefrontal cortex resources and repositories are referenced in omics work). (brase2023singlenucleusrnasequencingof pages 7-8, green2024cellularcommunitiesreveal pages 1-2)

7.2 UBERON suggestions

  • Brain (UBERON:0000955)
  • Cerebral cortex (UBERON:0000956)

8. Temporal development

The AA Workgroup explicitly incorporates asymptomatic biological AD and proposes an integrated biological–clinical staging approach across the continuum. (jack2024revisedcriteriafor pages 1-2)

Blood biomarkers are being positioned to enable earlier detection and staging—e.g., plasma biomarker performance for detecting brain Aβ pathology in non-demented cohorts. (niimi2024combiningplasmaaβ pages 7-8)

9. Inheritance and population

9.1 Epidemiology

This run did not retrieve a primary global epidemiology paper with prevalence/incidence rates for AD specifically; therefore, numeric prevalence/incidence statements are not provided here.

9.2 Genetic architecture / inheritance patterns

The retrieved omics study includes autosomal dominant AD carriers and late-onset risk-variant carriers, consistent with AD’s mixed architecture (rare Mendelian forms plus common polygenic susceptibility). (brase2023singlenucleusrnasequencingof pages 7-8)

10. Diagnostics

10.1 AA Workgroup revised diagnostic and staging criteria (2024)

Key definitions and performance anchors include: * AD can be defined biologically; ADNPC can exist without symptoms. (jack2024revisedcriteriafor pages 1-2) * Core 1 biomarkers (amyloid PET, approved CSF, accurate plasma biomarkers) are intended to map to plaques/tangles and support biological diagnosis. (jack2024revisedcriteriafor pages 1-2) * Core 1 plasma benchmark: the Workgroup proposes ≥90% accuracy vs amyloid PET for a standalone plasma biomarker used to establish amyloid pathology. (jack2024revisedcriteriafor pages 8-9) * Example reference performance: florbetapir PET visual reads showed 96% sensitivity / 100% specificity vs CERAD neuritic plaques; approved CSF assays showed approximately 88%/93% and 85%/94% sensitivity/specificity vs amyloid PET visual reads. (jack2024revisedcriteriafor pages 8-9)

10.2 Blood biomarkers (2023–2024 emphasis): plasma p-tau217

Real-world memory clinic performance: plasma p-tau217 (ECL immunoassay) detected CSF-defined Aβ pathology with AUC 0.91 and outperformed plasma p-tau181 (AUC 0.73). A two-threshold triage approach suggested that confirmatory lumbar puncture might be avoided in ~58–68% of cases depending on chosen sensitivity/specificity operating points. (dyer2024performanceofplasma pages 10-11)

Non-demented trial-ready / research cohorts: combining plasma Aβ measures and p-tau217 can yield AUCs approaching ~0.93–0.95 for predicting abnormal Aβ-PET, with best-performing models depending on clinical stage (CDR 0 vs 0.5) and inclusion of age/sex/APOE. (niimi2024combiningplasmaaβ pages 7-8)

10.3 Imaging and CSF biomarkers

The AA Workgroup uses amyloid PET and CSF assays as Core 1 standards and provides reference sensitivity/specificity anchors (see above). (jack2024revisedcriteriafor pages 8-9)

11. Outcome / prognosis

Evidence in the current retrieved set is insufficient to provide robust, citation-backed survival estimates, stage durations, or validated prognostic models.

12. Treatment

12.1 Current applications and real-world implementation (2023–2024)

Anti-amyloid monoclonal antibodies are described as the first generation of causal (pathology-targeting) therapies but with modest clinical effect sizes, safety/monitoring burdens, and eligibility constraints. The EADC investigators recommend selected patient use with treatment documentation in registries to inform real-world effectiveness and system readiness. (jessen2024progressinthe pages 1-2)

12.2 Safety considerations (ARIA)

A review summarizing aducanumab reports that while amyloid was reduced on PET, there was “no apparent improvement in cognitive function,” and ARIA occurred in ~40% of high-dose aducanumab-treated patients. (parums2024areviewof pages 4-6)

12.3 MAXO term suggestions

  • Anti-amyloid beta immunotherapy (monoclonal antibody therapy)
  • Magnetic resonance imaging monitoring
  • Lumbar puncture (confirmatory diagnostics)

Note: Detailed lecanemab/donanemab trial effect sizes and ARIA rates for those agents were not extractable from the currently captured evidence snippets.

13. Prevention

The prevention evidence emphasized in retrieved sources is consistent with a substantial preventable fraction of dementia via risk factor modification. A synthesis citing the Lancet Commission reports that a set of modifiable factors can account for up to ~40% of dementia cases. (parums2024areviewof pages 4-6)

14. Other species / natural disease

Not covered in the retrieved evidence.

15. Model organisms

Not covered in the retrieved evidence.

16. Notable 2023–2024 developments (concise analysis)

  1. Shift toward biological diagnosis: 2024 AA criteria explicitly formalize “biological AD” as diagnosable via biomarkers even without symptoms, motivated by the need to select patients for disease-modifying therapies. (jack2024revisedcriteriafor pages 1-2)
  2. Blood-based biomarker operationalization: Multiple 2024 studies support p-tau217 as a leading BBM with AUCs around 0.9 and plausible clinical triage workflows to reduce lumbar punctures and expand access. (dyer2024performanceofplasma pages 10-11, niimi2024combiningplasmaaβ pages 7-8)
  3. Systems and cell-state view of AD mechanisms: snRNA-seq studies in 2023–2024 strengthen the view that variant-associated microglial/astrocytic/oligodendroglial/neuron states are central to disease heterogeneity, suggesting multi-target and combination-therapy rationales. (brase2023singlenucleusrnasequencingof pages 7-8)

17. Evidence gaps / limitations of this report

Despite extensive retrieval, several template-required elements were not available as citation-backed facts in the captured evidence snippets: * ICD/MeSH/OMIM/Orphanet identifiers (should be filled from authoritative registries). * Quantitative prevalence/incidence statistics and survival estimates from primary epidemiologic cohorts. * Comprehensive phenotype frequencies mapped to HPO with percentages. * Detailed variant nomenclature, allele frequencies, and ClinVar classifications. * Detailed lecanemab/donanemab trial efficacy/safety metrics (beyond class-level summaries and aducanumab ARIA estimate).

These can be completed by targeted retrieval of (i) epidemiology (GBD dementia/AD-specific tables), (ii) GeneReviews/OMIM/ClinVar summaries for causative variants, and (iii) primary phase 3 trial publications for lecanemab and donanemab.

References

  1. (jack2024revisedcriteriafor pages 1-2): Clifford R. Jack, J. Scott Andrews, Thomas G. Beach, Teresa Buracchio, Billy Dunn, Ana Graf, Oskar Hansson, Carole Ho, William Jagust, Eric McDade, Jose Luis Molinuevo, Ozioma C. Okonkwo, Luca Pani, Michael S. Rafii, Philip Scheltens, Eric Siemers, Heather M. Snyder, Reisa Sperling, Charlotte E. Teunissen, and Maria C. Carrillo. Revised criteria for diagnosis and staging of alzheimer's disease: alzheimer's association workgroup. Alzheimer's & Dementia, 20:5143-5169, Jun 2024. URL: https://doi.org/10.1002/alz.13859, doi:10.1002/alz.13859. This article has 2357 citations and is from a highest quality peer-reviewed journal.

  2. (dyer2024performanceofplasma pages 10-11): Adam H. Dyer, Helena Dolphin, Antoinette O’Connor, Laura Morrison, Gavin Sedgwick, Conor Young, Emily Killeen, Conal Gallagher, Aoife McFeely, Eimear Connolly, Naomi Davey, Paul Claffey, Paddy Doyle, Shane Lyons, Christine Gaffney, Ruth Ennis, Cathy McHale, Jasmine Joseph, Graham Knight, Emmet Kelly, Cliona O’Farrelly, Aoife Fallon, Sean O’Dowd, Nollaig M. Bourke, and Sean P. Kennelly. Performance of plasma p-tau217 for the detection of amyloid-β positivity in a memory clinic cohort using an electrochemiluminescence immunoassay. Alzheimer's Research & Therapy, Aug 2024. URL: https://doi.org/10.1186/s13195-024-01555-z, doi:10.1186/s13195-024-01555-z. This article has 33 citations and is from a domain leading peer-reviewed journal.

  3. (niimi2024combiningplasmaaβ pages 7-8): Yoshiki Niimi, Shorena Janelidze, Kenichiro Sato, Naoki Tomita, Tadashi Tsukamoto, Takashi Kato, Kenji Yoshiyama, Hisatomo Kowa, Atsushi Iwata, Ryoko Ihara, Kazushi Suzuki, Kensaku Kasuga, Takeshi Ikeuchi, Kenji Ishii, Kengo Ito, Akinori Nakamura, Michio Senda, Theresa A. Day, Samantha C. Burnham, Leonardo Iaccarino, Michael J. Pontecorvo, Oskar Hansson, and Takeshi Iwatsubo. Combining plasma aβ and p-tau217 improves detection of brain amyloid in non-demented elderly. Alzheimer's Research & Therapy, May 2024. URL: https://doi.org/10.1186/s13195-024-01469-w, doi:10.1186/s13195-024-01469-w. This article has 68 citations and is from a domain leading peer-reviewed journal.

  4. (jack2024revisedcriteriafor pages 8-9): Clifford R. Jack, J. Scott Andrews, Thomas G. Beach, Teresa Buracchio, Billy Dunn, Ana Graf, Oskar Hansson, Carole Ho, William Jagust, Eric McDade, Jose Luis Molinuevo, Ozioma C. Okonkwo, Luca Pani, Michael S. Rafii, Philip Scheltens, Eric Siemers, Heather M. Snyder, Reisa Sperling, Charlotte E. Teunissen, and Maria C. Carrillo. Revised criteria for diagnosis and staging of alzheimer's disease: alzheimer's association workgroup. Alzheimer's & Dementia, 20:5143-5169, Jun 2024. URL: https://doi.org/10.1002/alz.13859, doi:10.1002/alz.13859. This article has 2357 citations and is from a highest quality peer-reviewed journal.

  5. (brase2023singlenucleusrnasequencingof pages 7-8): Logan Brase, Shih-Feng You, Ricardo D’Oliveira Albanus, Jorge L. Del-Aguila, Yaoyi Dai, Brenna C. Novotny, Carolina Soriano-Tarraga, Taitea Dykstra, Maria Victoria Fernandez, John P. Budde, Kristy Bergmann, John C. Morris, Randall J. Bateman, Richard J. Perrin, Eric McDade, Chengjie Xiong, Alison M. Goate, Martin Farlow, Greg T. Sutherland, Jonathan Kipnis, Celeste M. Karch, Bruno A. Benitez, and Oscar Harari. Single-nucleus rna-sequencing of autosomal dominant alzheimer disease and risk variant carriers. Nature Communications, Apr 2023. URL: https://doi.org/10.1038/s41467-023-37437-5, doi:10.1038/s41467-023-37437-5. This article has 95 citations and is from a highest quality peer-reviewed journal.

  6. (parums2024areviewof pages 4-6): Dinah V. Parums. A review of the current status of disease-modifying therapies and prevention of alzheimer’s disease. Medical Science Monitor, 30:e945091-1-e945091-7, May 2024. URL: https://doi.org/10.12659/msm.945091, doi:10.12659/msm.945091. This article has 39 citations and is from a peer-reviewed journal.

  7. (jessen2024progressinthe pages 1-2): Frank Jessen, M.G. Kramberger, D. Angioni, D. Aarsland, M. Balasa, K. Bennys, M. Boada, M. Boban, A. Chincarini, L. Exalto, A. Felbecker, K. Fliessbach, G.B. Frisoni, A.J. Garza-Martínez, T. Grimmer, B. Hanseeuw, J. Hort, A. Ivanoiu, S. Klöppel, L. Krajcovicova, B. McGuinness, P. Mecocci, A. de Mendonca, A. Nous, P.-J. Ousset, C. Paquet, R. Perneczky, O. Peters, M. Tabuas-Pereira, F. Piazza, D. Plantone, M. Riverol, A. Ruiz, G. Sacco, I. Santana, N. Scarmeas, E. Solje, E. Stefanova, S. Sutovsky, W. van der Flier, T. Welsh, A. Wimo, B. Winblad, L. Frölich, and S. Engelborghs. Progress in the treatment of alzheimer's disease is needed – position statement of european alzheimer's disease consortium (eadc) investigators. The Journal of Prevention of Alzheimer's Disease, 11:1212-1218, Oct 2024. URL: https://doi.org/10.14283/jpad.2024.153, doi:10.14283/jpad.2024.153. This article has 23 citations and is from a peer-reviewed journal.

  8. (OpenTargets Search: Alzheimer disease): Open Targets Query (Alzheimer disease, 39 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

  9. (green2024cellularcommunitiesreveal pages 1-2): Gilad Sahar Green, Masashi Fujita, Hyun-Sik Yang, Mariko Taga, Anael Cain, Cristin McCabe, Natacha Comandante-Lou, Charles C. White, Anna K. Schmidtner, Lu Zeng, Alina Sigalov, Yangling Wang, Aviv Regev, Hans-Ulrich Klein, Vilas Menon, David A. Bennett, Naomi Habib, and Philip L. De Jager. Cellular communities reveal trajectories of brain ageing and alzheimer's disease. Nature, 633:634-645, Aug 2024. URL: https://doi.org/10.1038/s41586-024-07871-6, doi:10.1038/s41586-024-07871-6. This article has 177 citations and is from a highest quality peer-reviewed journal.